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ABSTRACT

Diabetes mellitus (DM) is a metabolic disorder that affects an estimated 171
million people world wide. DM and its related complications are among the leading cause
of adult blindness and renal failure in the developed nations. Equally alarming, greater
than half of all patients with long-standing diabetes develop polyneuropathy, a
debilitating progressive deterioration of peripheral and autonomic nerves. Currently,
diabetic polyneuropathy (DPN) is untreatable. Maintenance of euglycemia as an indirect
means of delaying the development of diabetic complications is the recommended
therapeutic approach. Innovative treatment strategies designed to prevent or delay
peripheral nerve injury in the diabetic patient are critically needed. Moderate exercise is a
safe and integral approach to the management of patients with diabetes. Recent clinical
studies suggest that exercise may help in the treatment of DPN. However, the mechanism
by which exercise protects against diabetes-induced nerve dysfunction is unknown. In
this dissertation we hypothesized that forced-exercise protects against experimental DPN
by preventing glucose-associated alterations of voltage-gated calcium currents (VGCC)
in small diameter dorsal root ganglion (DRG) neurons. Using behavioral, nerveelectrophysiology and patch-clamp methodology we examined the functional
consequences of forced-exercise (treadmill, 5.4 km/week) on VGCC in dissociated small
diameter DRG neurons from rats conferred diabetic by streptozotocin (STZ) treatment.
Vehicle treated rats were used as controls. Exercised-STZ, rats in comparison to
xiv

sedentary-STZ, rats demonstrated a 4 week delay in the onset of tactile hyperalgesia that
was independent of changes in blood glucose levels. Interestingly, forced-exercise
induced protection against diabetes-induced tactile hyperalgesia was reversed in a dose
dependent manner by the opioid antagonist, naloxone. Forced-Exercise also prevented
peripheral nerve conduction deficits in STZ–treated rats. Small diameter DRG neurons
harvested from hyperglycemic sedentary-STZ rats with demonstrated hyperalgesia
exhibited 2-fold increase in peak high-voltage activated (HVA) Ca2+ current density and
low-voltage activated (LVA) Ca2+ current component. The steady-state inactivation (SSI)
(measure of channel availability) of LVA currents demonstrated a rightward shift in the
sedentary-STZ rats (+7.5 mV shift; V50 = -50.9 ± 0.6 mV; vehicle treated rats V50 = -58.4
± 0.9 mV). Forced-exercise prevented the increase in both, peak HVA Ca2+ current
density and LVA SSI shift (V50 = -58.2 ± 1.4 mV), but did not alter LVA current
component. We conclude that forced-exercise delayed the onset of diabetic tactile
hyperalgesia by preventing the alteration of VGCCs in small diameter DRG neurons,
possibly by decreasing total calcium influx and dampening neuronal over-excitability.

xv

CHAPTER ONE
INTRODUCTION
STATEMENT OF PROBLEM

Diabetes mellitus (DM) is a group of metabolic disorders sharing hyperglycemia
as a common phenotype that, when poorly managed, results in debilitating retinal, renal,
and neurologic complications (Nathan, 1996). The prevalence of DM and its
hyperglycemic-related complications are at near epidemic proportions in the U.S.,
affecting approximately 24 million Americans, or greater than 8% of the population
(Center for Disease Control, 2005). In 2007, almost 25% of the population aged 60 years
and above had diabetes. In addition, another 57 million people are estimated to have prediabetes, a condition that increases the risk of developing DM. (Center for Disease
Control, 2008). Strikingly, DM is the seventh leading cause of death in the United States
and globally 5% of all deaths are attributed to DM. Complications of DM, which include
heart diseases, blindness, kidney failure, and lower limb amputations pose a significant
financial burden on the health care system. The direct and indirect costs in the U.S. for
medical services and lost productivity due to DM is approximately 132 billion dollars
(Hogan et al., 2003).
Greater than half of all patients with DM develop neurological complications
(Pirart, 1977). Although varied, the most common neurologic complication seen among
16
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DM patients includes distal symmetric polyneuropathy (DPN), a progressive
deterioration of the peripheral and autonomic nerves. DPN is causally associated with
greater than 200,000 cases of diabetic foot ulcers and 71,000 amputations per year
(Center for Disease Control, 2008). The primary risk factor for DPN is hyperglycemia
(Perkins et al., 2001). Independent secondary risk factors include cigarette smoking,
hypercholesterolemia, alcohol consumption and hypertension (Adler et al., 1997).
Clinically, DPN is characterized by chronic peripheral pain described as a burning,
pricking or tingling sensation with symmetric stocking glove distribution. Several
pathogenic mechanisms have been proposed to explain the development of DPN,
including activation of the polyol pathway secondary to hyperglycemia, accumulation of
advanced glycation end products, vascular insufficiency, neurotrophic factor deficiency,
and neuronal membrane ion channel dysfunction (Gooch and Podwall, 2004).
Current therapeutic interventions for the treatment of DPN are largely limited to
pain management and strict glycemic control. Gabapentin, tricyclic antidepressants,
duloxetine (serotonine-norepinephrine reuptake inhibitor), opioids, and topical capsaicin
cream are currently prescribed, with mixed results. Results from clinical trials using
nerve growth factor therapy, aldose reductase inhibitors, or acetyl carnitine have
experienced limited success (Ziegler and Luft, 2002). Innovative interventional or
preventive strategies are required to address the needs of the ever growing DPN patient
population.
Exercise training, in combination with pharmacological intervention, is now
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recognized as a cornerstone of treatment for DM. Aerobic exercise without or with
resistance training has shown to have beneficial effects in DM (Castaneda et al., 2002).
Previous studies have shown that long term aerobic exercise can modify the natural
history of DPN in diabetic patients (Balducci et al., 2006). Physical exercise, in addition
to improving blood glucose control, also exerts protective effects on cardiovascular and
endothelial function (Maiorana et al., 2001; Fuchsjager-Mayrl et al., 2002). Less,
however, is known about the effects of exercise on the onset and progression of diabetes
associated complications including DPN (Tesfaye et al., 1992; Richardson et al., 2001).
Patients with DPN often exhibit hyperalgesia or enhanced sensitivity to pain
(Baron et al., 2009), which contributes to the morbidity in diabetes. The cause of
impaired pain tolerance remains unclear. Early experimental studies suggest that
intermittent hyperglycemia damages sensory neurons and increases spontaneous C-fiber
firing, resulting in neuropathic pain (Chen and Levine, 2001). Evidence to support a
protective effect of moderate aerobic exercise against the development of neuropathic
complications in diabetic patients is mounting (Balducci et al., 2006), raising interest in
aerobic exercise as a putative therapeutic intervention for the management of pain in
diabetic neuropathy. The cellular mechanism(s) by which neuropathic pain develops in
the diabetic patient is poorly understood, but may involve remodeling of voltage- or
ligand-gated ion channels (Hall et al., 1995; Cao, 2006; Jagodic et al., 2007), resulting in
abnormal enhancement of sensory neuron excitability (Ikeda and Dunlap, 2007).
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Little is known about the effect of exercise on the functioning of ion channels.
Modulation of voltage gated calcium channels (VGCC) in response to exercise has been
recently reported in swine coronary smooth muscle cells (Bowles, 2000) and treadmill
trained rat ventricular myocytes (Wang et al., 2008). However, there have been no studies
to date describing the effect of exercise on neuronal VGCC’s associated with neuropathic
pain.
In this dissertative research study, we examined whether exercise attenuates the
onset and progression of diabetic neuropathy in an animal model of DM. Further, we
examined whether forced-exercise can prevent or delay the onset of neuropathic pain by
attenuating diabetes-associated increased functioning of voltage-gated calcium channels
in the dorsal root ganglion neurons.
HYPOTHESIS
Forced-exercise will protect against the onset of tactile hyperalgesia in
streptozotocin-induced hyperglycemic rats by preventing the over-activity of voltagegated calcium channels in the small diameter dorsal root ganglion neurons.
SPECIFIC AIMS
This hypothesis will be tested using the following three Specific aims:
Specific Aim 1.
We will determine the effect of forced-exercise on the onset and progression of
peripheral nerve injury in STZ-induced diabetic rats, as quantitated by evoked-response
electrophysiology,

tactile

withdrawal

threshold,

and

thermal-evoked

hind-paw
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withdrawal latency response times. Vehicle- and STZ-treated non-exercised rats will be
included as sedentary controls for comparison.
Specific Aim 2.
We will determine the effect of forced-exercise on high- and low-voltage
activated Ca2+ current densities and low-voltage activated Ca2+channel steady state
properties in small diameter dorsal root ganglion neurons harvested from STZ-treated
rats, as quantitated by whole cell patch-clamp electrophysiology. Non-exercised veh-and
STZ-treated rats will be used as controls.
Specific Aim 3.
We will determine the effect of high D-glucose on current densities, channel
kinetics and steady state properties from HEK-293 cells stably transfected with the
CaV3.2 α1H channel subunit, using whole cell patch-clamp electrophysiology.
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LITERATURE REVIEW
DIABETES MELLITUS
Insulin, produced by the β cells in the islets of Langerhans of the endocrine
pancreas, is responsible for glucose uptake into cells of the liver, muscle and fat.
Dysregulation of insulin production, secretion, or action results in abnormalities of blood
glucose homeostasis, resulting in diabetes mellitus (DM). The syndrome of DM
comprises a group of chronic disorders, sharing hyperglycemia as a common phenotype
(Table 1). Overtime patients with long term DM develop multi-organ complications
affecting the eye, kidney and peripheral/autonomic nerves (Nathan, 1996). The hallmark
of DM is a sustained increase in blood glucose levels, with clinical diagnosis primarily
based on blood glucose level measurements (Table 2).
DM is classified into several types (Table 1), of which DM type 1 and 2
(Himsworth, 1949) are more common. DM type 1 occurs as a result of autoimmunity that
ultimately destroys the insulin- producing pancreatic β cells (Mandrup-Poulsen, 1996),
leading to the development of severe hypoinsulinemia. The autoimmune processes are
likely to be initiated by unknown environmental triggers in genetically susceptible
individuals (Donner et al., 1997). In contrast, DM type 2 is a multi-factorial disease with
genetic and life-style choices (poor eating habits, physical inactivity, chronic stress)
playing a major role (Anderson et al., 2003). Type 2 DM in its initial phase exhibits
enhanced insulin levels secondary to cellular insulin resistance and eventually
demonstrates insulin deficiency (Reaven, 1988; Mahler and Adler, 1999). Increased
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glucose production and decreased glycogen storage, secondary to insulin resistance in the
liver, further contribute to the development of hyperglycemia in type 2 DM. Insulin
resistance of adipocytes leads to enhanced free fatty acid flux from adipose tissue, which
in turn increases liver lipid and triglyceride production resulting in dyslipidemia (Dennis
L. Kasper, 2010).

Primary Pathology

Etiology

Type 1 Diabetes
Mellitus

β cell destruction leading to
insulin deficiency

Auto immune mediated,
Idiopathic

Type 2 Diabetes
Mellitus

Peripheral resistance to insulin

Genetic,
Life-style choices

Gestational Diabetes
Mellitus

Reduced insulin secretion
Enhanced insulin resistance

Idiopathic

Other types of Diabetes Mellitus:
Genetic defects in beta cell function and insulin action- Maturity onset diabetes of the
young (MODY), Lipodystrophy syndromes
Disorders of the exocrine pancreas- Pancreatitis, Cystic fibrosis
Endocrinopathies – Acromegaly, Cushing’s, Glucagonoma
Iatrogenic- Glucocorticoids, Clozapine, Thiazides

Table 1. Classification of Diabetes Mellitus
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Fasting

2 hr post prandial

Normal

< 100 mg/dL

< 140 mg/dL

Pre diabetes

100 – 125 mg/dL

140 – 200 mg/dL

Diabetes

≥ 126 mg/dL

≥ 200 mg/dL

Table 2. Clinical classification of glucose tolerance based on plasma glucose levels.

Epidemiology of DM
The prevalence of DM and its related complications are at near epidemic
proportions. According to the World Health Organization, the prevalence for all age
groups worldwide is 2.8% and is predicted to increase up to 4.4% by 2030 (Wild et al.,
2004). In the U.S., DM affects an estimated 8% of the population (Center for Disease
Control, 2005). In addition to human morbidity and mortality, DM and its complications
represent a substantial economic burden on the health care system.
Complications of DM
Chronic complications of DM involve multiple organs and are responsible for the
majority of mortality associated with diabetes. The incidence of complications increases
along with the duration of hyperglycemia (U.K.prospective-diabetes-study, 1995), hence
chronic complications are more common during the second decade of DM (Powers,
2006). Chronic complications of DM can be classified into non-vascular and vascular
disorders. Vascular disorders affect both macro- and micro-vascular blood vessels
leading to a host of pathological conditions involving the vasculature of the heart
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(coronary artery disease), brain (cerebrovascular disease), eye (retinopathy), kidney
(nephropathy), and nerves (neuropathy) (Mahler and Adler, 1999).
Acute

complications

of

DM

include

ketoacidosis

and

hyperglycemic

hyperosmolar state (HHS). Diabetic ketoacidosis and HHS are both potentially serious
conditions characterized by severe hyperglycemia, blood electrolyte abnormalities,
progressing to unconsciousness and if untreated, death (Umpierrez and Kitabchi, 2003;
Kitabchi and Nyenwe, 2006).
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DIABETIC NEUROPATHY
It is estimated that more than half of all patients with DM develop diabetic
neuropathy. The prevalence varies from 1% within the first year of diagnosis of DM to
more than 50% after 25 years (Pirart, 1977). The Rochester Diabetic Neuropathy Study
found that approximately 66% of insulin-dependent DM patients and 59% of non-insulin
dependent DM patients had some forms of diabetic neuropathy (Dyck et al., 1993).
The ‘syndrome’ of diabetic neuropathy is a microvascular complication of DM
affecting the sensory, motor and autonomic nerves. Patients with diabetic neuropathy
present with a wide range of symptoms from altered tactile sensations to cardiac
arrhythmias. Table 3 summarizes the features of different types of diabetic neuropathies.
Of the various types, symmetrical polyneuropathy, usually referred as diabetic
polyneuropathy (DPN), is more common among the diabetic population. DPN patients
exhibit altered perception to vibratory, tactile, pressure hot and cold stimuli along with
slower nerve conduction velocity (Lipnick and Lee, 1996). DPN is associated with more
than 71,000 foot amputations per year and 200,000 foot ulcers (CDC, 2007).
Pathogenic mechanisms of diabetes-associated nerve injury
Neurons, unlike muscle, liver, and fat, do not require insulin for glucose uptake
(Greene and Winegrad, 1979). However, glucose is actively transported across the blood
brain barrier (BBB) and the blood nerve barrier (BNB) for its metabolism (Rechthand et
al., 1985; Kumagai et al., 1994). The endothelium of these vascular barriers uses the
insulin-insensitive GLUT-1 transporter to facilitate glucose transport (Pardridge et al.,
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1990). The absence of insulin-regulation in neurons makes these cells more prone to
hyperglycemic insult (Thorburn et al., 1990).

Type

Primary Signs and Symptoms

Distal symmetric polyneuropathy

Paresthesias, numbness, hyperesthesias, ataxia

Diabetic polyradiculopathy

Severe disabling pain in the distribution of the
affected nerve roots, with motor weakness

Diabetic mononeuropathy

Dysfunction of an isolated cranial nerve or
peripheral nerve. Features include diplopia
(III nerve is commonly affected), facial
weakness and pain

Autonomic neuropathy

Cardiac arrhythmia, orthostasis, impotence
and constipation

Table 3. Types, symptoms, and signs of diabetic neuropathy.

After its facilitated entry into the cell, D-glucose undergoes hexokinase mediated
phosphorylation as it enters the glycolytic pathway. In contrast, the increased blood
glucose load in diabetes saturates the hexokinase enzyme system. Rising intra-cellular
glucose concentrations approach the Km of aldose reductase, an enzyme that channels
excess glucose into the polyol pathway (Oates, 2002). The main byproducts of the polyol
pathway are sorbitol and fructose.
Sorbitol is a poorly permeable intracellular osmolyte that enables cells to maintain
interstitial osmotic pressure. Accumulation of sorbitol results in osmotic disturbances
within the cell which de-stabilizes the uptake of carrier proteins for other osmolytes like
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myo-inositol and taurine (Bagnasco et al., 1986). Impaired myo-inositol-dependent
phosphoinositide signaling pathway leads to reduced activity of the Na+/K+ ATPase,
necessary for the maintenance of nerve action potential propagation and nerve conduction
velocity (Nishimura et al., 1987). In neurons, activation of aldose reductase compromises
the recycling of the antioxidant glutathione, by depletion of NADPH, resulting in the
generation of damaging hydroxyl free radicals and concurrently altering the redox state of
the cell.
Non-enzymatic glycation is another mechanism implicated in development of
diabetic neuropathy. Reducing sugars like glucose and fructose non-enzymatically react
with free amino groups of lipids, proteins and nucleic acids to form Schiff bases,
ketamines, and Amadori products, which undergo slow spontaneous molecular
arrangement (Amadori rearrangement) forming stable advanced glycation end-products
(AGE) (Singh et al., 2001; Jakus and Rietbrock, 2004). Activation of AGE receptors
(RAGE) leads to a variety of detrimental affects, including activation of proinflammatory cascades, sustained cellular dysfunction and tissue destruction (Ahmed et
al., 2003; Haslbeck et al., 2007). Table 4 summarizes diabetes mediated cellular
mechanisms that are implicated in nerve injury.
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Mechanism

Key features

Polyol pathway

Increased sorbitol and fructose production
Decreased NADPH
Decreased glutathione
Decreased myoinositol

Oxidative stress

Hydrogen peroxide formation
DNA strand breakage

Glycation of proteins

Formation of advance glycated end-products (AGE)
Activation of receptors for AGE (RAGE)

Dysfunctional intra-cellular
signaling

Aberrant activation of MAP kinases

Reduced trophic support

Nerve growth factor, insulin like growth factor-1,
brain derived trophic factor

Table 4. Mechanisms of diabetes induced nerve injury.

Neuropathic pain in diabetic neuropathy
Up to 20% of diabetic patients with neuropathy describe abnormal peripheral
sensations (Boulton et al., 1983; Partanen et al., 1995), including spontaneous pain,
exaggerated perception of pain to mildly noxious (hyperalgesia) or innocuous stimuli
(allodynia), and the feeling of pins and needles (paresthesia). Painful diabetic neuropathy
is extremely disabling and greatly affects the quality of life.
Altered nociception is reported in patients with either insulin dependent or insulin
resistant DM, suggesting that the onset of pain is not entirely resultant from insulin
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deficiency. Interestingly, healthy non-diabetic subjects show marked decreases in pain
thresholds in response to glucose infusions (Morley et al., 1984). In some cases, diabetic
patients

demonstrate alleviation of neuropathic symptoms upon improved glycemic

control (DCCT, 1995). However in some cases, pain persists for many years even after
strict glycemic control (Calcutt, 2002). These findings suggest that blood glucose control
alone is insufficient to prevent the development of altered nociception in DM.
Experimental animal models of diabetic neuropathy
Experimental animal models that demonstrate similar pathological features of DM
and its associated complications are vital in understanding the pathogenesis of DPN.
Animal models of DPN provide opportunities to design and test new treatment options
for improved management of the neuropathic diabetic patient. As in human insulindependent diabetes, type 1 animal models of DM demonstrate characteristic features
including insulitis (Zuccollo et al., 1999), pancreatic β cell death (Yang et al., 2003), and
the involvement of immunological (Kay et al., 2000; Eizirik and Mandrup-Poulsen, 2001)
and Major Histocompatability Complex (MHC) in disease development (Hashimoto et
al., 1994; Martin et al., 1999). By comparison, the type 2 animal models, (Table 5)
demonstrate insulin resistance and beta cell failure along with prominent characteristics
similar to human type 2 DM, including obesity (Zhang et al., 1994), dyslipidaemia, and
hypertension (Marquie et al., 1991; Ziv et al., 1999).
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Animal Models of Type 1 DM
Drug induced
Streptozotocin, Alloxan
Spontaneously insulin-dependent
Non-obese diabetic mouse (NOD)
Bio breeding rat (BB)
Long-Evans Tokushima lean rat
Keeshond dog
New Zealand white rabbit
Macaca Nigra

Animal Models of Type 2 DM
ob/ob mouse (Leptin-deficient)
db/db mouse (Leptin-receptor
deficient)
fa/fa Zucker rat (Obesity phenotype)
KK mouse
Goto Kakizaki rat (Non-obese)
NSY mouse
Israeli sand rat (Leptin-resistant)
Fat-fed streptozotocin-treated rat
Diabetic Torri rat (Non-obese)
New Zealand obese mouse
Otsuka LE Tokushima fatty rat

Table 5. Animal models of DM and its subtypes, modified from (Rees and Alcolado,
2005)

Streptozotocin (STZ)-induced DM
Streptozotocin

[N-(methylnitrosocarbamoyl)-α-D-glucosamine]

is

an

antineoplastic antibiotic produced from the gram positive bacteria, Streptomyces
achromogenes (Brian Rodrigues, 1999). STZ is used mainly in the treatment of
pancreatic islet cell tumors (Kouvaraki et al., 2004). While the diabetogenic property of
STZ was first reported by Upjohn laboratories, Rakieten et al. first described the β-cell
necrosis property of STZ (Rakieten et al., 1963).
The chemical structure of STZ comprises of a glucose molecule with a cytotoxic
nitrosourea side chain. The glucose moiety directs the STZ molecule to the insulin
producing pancreatic beta cells (Johansson and Tjalve, 1978), where it is selectively
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taken up by GLUT-2 for transport into the pancreatic β cell (Kawada et al., 1987;
Schnedl et al., 1994). Once inside, the nitroso moiety decomposes to form a highly
reactive carbonium ion that causes DNA breaks by alkylating DNA bases (Uchigata et
al., 1982). DNA damage activates poly (ADP-ribose) synthetase, a nuclear enzyme
essential for DNA repair. NAD+ is used as a substrate by poly (ADP-ribose) synthetase,
and following STZ treatment, depletion of NAD+ occurs within 20 minutes (Wilson et al.,
1984). In addition to the DNA alkylating property of STZ, oxidative stress due to the
production of hydrogen peroxide (Robbins et al., 1980) and nitric oxide have been
proposed (Turk et al., 1993; Kwon et al., 1994).
Changes in blood glucose and insulin levels follow a triphasic pattern within the
first 24h upon in vivo STZ administration. Initial hyperglycemia lasting for
approximately 1h is followed by marked hypoglycemia (~6 h) due to the secondary
release of pancreatic insulin, resultant from β cell degranulation (Junod et al., 1969).
Stable hyperglycemia develops within 24h to 48 h and remains elevated three to four
times the normal blood glucose level. Even though the STZ treated animals are insulin
deficient, they neither develop diabetic ketoacidosis nor do they require exogenous
insulin for survival (Junod et al., 1969; Brian Rodrigues, 1999). However complications
similar to that seen in human DM do develop, including cardiac (Litwin et al., 1990),
vasculature (Hill and Ege, 1994), retina (Bensaoula and Ottlecz, 2001), kidney (Okada et
al., 1992) and the nervous system (Duran-Jimenez et al., 2009) abnormalities.
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STZ-induced diabetic polyneuropathy
The STZ-treated rodent model used in this study develops peripheral nerve
complications that closely mimic some of the changes seen human DPN. STZ-treated
animals develop hyperalgesia to tactile (Ahlgren and Levine, 1993; Calcutt et al., 1996),
thermal (Forman et al., 1986; Lee and McCarty, 1990), and chemical noxious stimuli
(Courteix et al., 1993; Malmberg et al., 1993), defined here as neuropathic pain. Nerve
morphological changes seen in STZ-induced DPN include decreased axonal fiber size
(Medori et al., 1988; Yagihashi et al., 1990a), nodal swelling, and segmental
demyelination (Sima et al., 1988b; Yagihashi et al., 1990b) with concomitant decreased
nerve conduction velocity. Axonal degeneration and fiber loss, consistent findings in
human diabetic neuropathy, however, is not observed in the STZ diabetic model
(Malcangio and Tomlinson, 1998).
Treatment options in diabetic neuropathy
Current therapeutic interventions for the treatment of DPN are less than
satisfactory. Strict glycemic control is still the mainstay of treatment, but blood glucose
control alone does not prevent development or progression of DPN. Gabapentin, tricyclic
antidepressants, duloxetine (serotonin-norepinephrine reuptake inhibitor), opioids and
topical capsaicin are currently prescribed, with mixed results. Clinical trials using nerve
growth factor replacement therapy, aldose reductase inhibitors, and acetyl carnitine
supplementation have been largely disappointing. Innovative interventional or
preventive strategies are critically needed to advance the care of patients with DPN.
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Exercise as a therapeutic strategy
Exercise has numerous beneficial effects that promote protection, both at the level
of central and peripheral nervous system. In the central nervous system, exercise
facilitates recovery from traumatic brain injury by normalizing the levels of myelin
derived growth inhibitory molecules like MAG (myelin-associated glycoprotein) and
Nogo-A, and promotes axonal growth (Chytrova et al., 2008). In spinal-cord injury (SCI)
models, exercise promotes functional motor recovery by inducing axonal growth and
synapse formation (Doyle and Roberts, 2004; Goldshmit et al., 2008). Exercise has also
been used in combination with a wide variety of therapeutic measures including stem
cells therapy (Carvalho et al., 2008; Foret et al., 2010), melatonin therapy (Park et al.,
2010) and neurotrophin therapy (Nothias et al., 2005) in SCI animal models.
Improvements in cognition and memory have been observed with exercise in animal
models of aging and dementia (Kramer et al., 2006; Nichol et al., 2009). Exercise
protects against diabetes-associated decreases in LTP (long-term potentiation) induction
(Reisi et al., 2010), suggesting a facilitative role in synaptic plasticity. Overall, growing
evidence supports a more than passive role of exercise in protection of neuronal function
against a wide array of physiological and non-physiological CNS insults.
Moderate exercise is now considered a well established, safe, and integral
approach to the management of patients with DM (Lynch et al., 1996; Knowler et al.,
2002; Tanasescu et al., 2003). Recent studies have demonstrated that aerobic exercise
significantly decreases the complications arising from DM induced microvascular lesions
(Estacio et al., 1998). Therapeutic interventions such as aerobic exercise may enhance
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blood flow to the peripheral nerves and improve outcome measures of diabetic
neuropathy (Fisher et al., 2007). Exercise attenuates tactile hyperalgesia in a spinal cord
injury model (Hutchinson et al., 2004). Smith et al. observed decreased diabetes-induced
neuropathic pain and improved sural nerve responses with diet and exercise-mediated life
style intervention. There is however no mechanistic or observational data addressing the
protective effect of exercise on neuropathic pain in experimental diabetes.
Exercise and voltage-gated calcium channels
Voltage-gated Ca2+ channels (VGCC) are protein complexes present in the plamsa
membrane of virtually all excitable cells. Plasma membrane depolarization triggers the
opening of VGCC’s, resulting in the rapid influx of extracellular Ca2+ which is known to
be involved in various cellular processes including neurotransmitter release and cellular
excitability. Recent studies have demonstrated that VGCC’s play an important role in
pain signaling. The cellular mechanism(s) by which neuropathic pain develops in the
diabetic patient is poorly understood, but may involve remodeling of voltage- or ligandgated ion channels (Carbone and Lux, 1984; Nowycky et al., 1985; Cao, 2006) leading to
abnormal enhancement of sensory neuron excitability (Ikeda and Dunlap, 2007) and
altered neurotransmitter release.
The impact of exercise on the function of voltage-gated ion channels remains
unclear. Experimental exercise has been shown to increase L-type peak calcium current
density in swine arterial smooth muscles (Bowles, 2000). In contrast, ventricular
myocytes from swim-trained rats demonstrate reduced peak L-type Ca2+ current density,
compared to sedentary controls (Wang et al., 2008). However, there is a deficit of
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reported studies examining the effect of exercise on neuronal VGCC’s associated with
diabetes-induced neuropathic pain.
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VOLTAGE GATED CALCIUM CHANNELS
The plasma membranes of virtually all excitable cells, including neurons express
voltage gated calcium channels (VGCC). VGCC’s are oligomeric protein complexes
consisting of different central pore-forming α1 subunit isoforms (Table 6), surrounded by
several auxiliary subunits (β, α2δ and γ) which serve to modulate the function of the α1
subunit (Castellano et al., 1993; Felix, 1999) (Figure 1B). The complex consists of four
distinct domains (I-IV), each exhibiting six (S1-S6) helical membrane spanning regions.
The S4 helices in each of the four domains are enriched with positively charged amino
acid residues that allow the VGCC’s to detect changes in membrane potential. The
selective hydrophilic pore is formed by the coalescence of the reentrant p-loops between
S5 and S6 of each of the four domains. Plasma membrane depolarization triggers the
opening of VGCC’s, resulting in the rapid influx of extracellular Ca2+ involved in various
cellular processes including neuronal excitability and neurotransmitter release (Catterall,
2000; Cao, 2006) (Table 6).
There are several distinct families of VGCC’s defined by various molecular,
pharmacological, and genetic criteria (Tsien et al., 1988; Bean, 1989). In general,
VGCC’s can be characterized by their activation range into two basic categories, highvoltage (HVA) and low-voltage (LVA) activated Ca2+ channels. The HVA Ca2+ channels
open in response to large change in membrane potentials and include the CaV1(L) and
CaV2 (P, Q, N, R) families of calcium channels. The LVA Ca2+ channels open in
response to small changes in membrane potential and include the CaV3 (T) family of Ca2+
channels.
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Ca2+
Channel

CaV1.1

α1
subunit

α1S

Gene

CACNA1S

Current

L

Blocker

Localization

dyhdropyridine

Skeletal
muscle

CaV1.2

α1C

CACNA1C

L

dyhdropyridine

Cardiac
muscle
Neurons
Endocrine
cells

CaV1.3

α1D

CACNA1D

L

dyhdropyridine

Neurons,
Endocrine
cells

CaV1.4

α1F

CACNA1F

L

α1A

CACNA1A

P/Q

α1B

CACNA1B

N

CaV2.1
CaV2.2

CaV2.3

CaV3.1

α1E

α1G

CACNA1E

CACNA1G

R

T

CaV3.2

α1H

CACNA1H

T

CaV3.3

α1I

CACNA1I

T

Retina
ω-agatoxin
1Va

Nerve
terminals
Dendrites

ω-conotoxinGVIA

SNX-482

Cell bodies,
dendrites
nerve
terminals

nickel
ethosuximide
mibefradil

Cardiac
muscle
Skeletal
muscle
Neuron

mibefradil

Cardiac
muscle
Neuron
Neuron

Table 6. Pharmacology and function of the α1 Ca2+ channel subunit.

Function
Calcium
homeostasis,
gene expression
and excitation –
contraction
coupling
Excitationcontraction
coupling,
hormone
secretion, gene
regulation
Hormone
secretion and
gene regulation
Neurotransmitter
release
Neurotransmitter
release, dendritic
Ca2+ transients
Neurotransmitter
release, dendritic
Ca2+ transients
Ca2+ dependent
AP’s
neurotransmitter
release, dendritic
Ca2+ transients
Action potential
generation
Rhythm pattern
generation
Action potential
generation
Rhythm pattern
generation
Rhythm pattern
generation
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A

B

Figure 1. Schematic of voltage-gated calcium channel.
(A) Cartoon depicting the various subunits of the voltage-gated Ca2+ channel and (B)
structural features of the central pore-forming α1 subunit. Figure reproduced from
(Tedford and Zamponi, 2006).
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High-voltage activated Ca2+ channel isoforms
HVA Ca2+ channels activate in response to large changes in membrane potentials
(Fox et al., 1987). Opening of some HVA Ca2+ channel types facilitates neurotransmitter
release, excitation-contraction coupling, and secretion. The different HVA Ca2+ channels
are described below.
CaV 1 (L- type) family of Ca2+ channels
L type currents are predominant in cardiac, smooth, skeletal muscles and brain.
They are also present in endocrine cells, where they are known to play a role in hormone
secretion (Milani et al., 1990). CaV 1 channels located on the cell body and dendrites of
nerves regulate gene expression and integrate synaptic inputs (Bean, 1989). L type
currents are distinguished by their high voltage dependence of activation, slower voltage
dependent inactivation, relatively large single channel conductance, regulation by
cAMP–dependent phosphorylation pathways, and sensitivity to dihydropyridines,
phenylalkylamines and benzothiazepines (Reuter, 1983; Hadley and Lederer, 1991).
CaV 2 (P/Q, N, R - type) family of Ca2+ channels
CaV 2.1 (P/Q) Ca2+ channels are prominently expressed on the dendrites and pre-synaptic
nerve terminal of neurons. Currents from the P – type Ca2+ channels were first recorded
in the cerebellar Purkinje neuron (Llinas et al., 1989) and are characterized by high
affinity binding of ω- agatoxin IVA (Mintz et al., 1992). In comparison the Q-type Ca2+
currents present in the cerebellar granule cells (Randall and Tsien, 1995) exhibit a lower
affinity binding to ω- agatoxin IVA (Stea et al., 1994). P/Q-type channel currents are
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primarily regulated by G protein coupled pathways (Hille, 1994) and are functionally
involved in initiating synaptic transmission (Catterall, 2000).
The CaV2.2 (N-type) Ca2+ channels are expressed exclusively in the nervous
system, with primary afferent sensory neurons and the superficial layer of the dorsal horn
showing high expression levels (Bourinet and Zamponi, 2005). N-type currents are
distinguished by their intermediate voltage dependence and a rate of inactivation which is
more negative and faster than L-type currents but more positive and slower than T-type
currents. The cone-snail peptide, ω-conotoxin GVIA irreversibly inhibits CaV2.2 Ca2+
channels and has been used as a primary tool to distinguish N-type from other
Ca2+currents. Modulation of CaV2.2 channel function is primarily through GPCR
mediated pathways (Ikeda, 1996; Ikeda and Dunlap, 1999). Recently, CaV 2.2 channels
have been implicated in pain signaling. In the superficial layer of the dorsal horn, CaV 2.2
Ca2+ channels regulate the release of the nociceptive neurotransmitters including
glutamate and neuropeptides (Smith et al., 2002). Accordingly, CaV 2.2 channel knockout
mice do not develop inflammatory or neuropathic pain associated mechanical
hyperalgesia, suggesting a role for CaV2.2 channels in nociception (Kim et al., 2001;
Saegusa et al., 2001).
The CaV2.3 (R-type) Ca2+ channel currents are known to be resistant to most Ca2+
channel blockers. These channels have been thought to play a crucial role in regulating
the release of neurotransmitters (Wu et al., 1998; Albillos et al., 2000). Also, they may
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participate in Ca2+ influx in response to action potentials (Magee and Johnston, 1995;
Sabatini and Svoboda, 2000).
Low-voltage activated Ca2+ channels
CaV3 family (T-type) Ca2+ channels
The CaV3 family of calcium channels are activated by small depolarization of the
cell membrane, hence commonly referred to as – low-voltage activated calcium channels.
The CaV3 family comprises of three isoforms based on biophysical and pharmacological
properties, namely CaV3.1 α1G, CaV3.2 α1H, and CaV3.3 α1I (Cribbs et al., 1998; PerezReyes et al., 1998).

The first recording of low-voltage activated calcium currents was

made in mouse neuroblastoma cell line (N1E-115) (Moolenaar and Spector, 1978). Ttype calcium channels are expressed in the nervous system (Carbone and Lux, 1984), the
heart (Nilius et al., 1985), kidneys (Gordienko et al., 1994), endocrine organs, smooth
muscles (Brueggemann et al., 2005) and sperm (Arnoult et al., 1996). They have been
reported to be involved in the pathophysiology of cardiac arrhythmias (Satoh, 1995),
sleep disorders (McCormick and Bal, 1997), epilepsy (Tsakiridou et al., 1995),
nociception (Kim et al., 2003), and fertilization (Talavera and Nilius, 2006). Biologically,
these channels modulate vital cellular functions including excitability (Chemin et al.,
2002), secretion (Bhattacharjee et al., 1997), differentiation (Bijlenga et al., 2000),
proliferation (Lory et al., 2006) and excitation-contraction coupling (Zhou and January,
1998).
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T-type Ca2+ currents have several unique electrophysiological characteristics that
separate them from the high-voltage activated calcium channels. T-type Ca2+ channels
begin to activate after small depolarization of the cell membrane and exhibit rapidly
inactivating transient currents in response to sustained depolarization. Upon
repolarization, they close slowly resulting in the generation of tail currents with slow
deactivation time constant. (Perez-Reyes, 2003). T-type Ca2+ channels open at small
voltage ranges, but do not inactivate completely, resulting in window currents which may
be essential for regulating intracellular Ca2+ concentration (Bijlenga et al., 2000).
Role of voltage-gated Ca2+ channels in neuropathic pain
Modulation and transmission of painful stimuli from the periphery to the CNS is
mediated at the level of DRG by a variety of ion channels including the persistent Na+
channels, inward rectifying K+ channels and voltage gated Ca2+ channels (Woolf and
Mannion, 1999; Julius and Basbaum, 2001). Recent studies have demonstrated that
VGCC’s play an important role in pain signaling. VGCC’s modulate key aspects of pain
transmission by regulating neuronal properties such as excitability, generation and
propagation of action potential and release of nociceptive neurotransmitters in sensory
neurons.
Voltage activated

N-, T- and to some extent, P/Q-type Ca2+ channels are

established mediators of pain signaling (Zamponi et al., 2009), while the role of L- and
R-type in nociception is uncertain (Altier and Zamponi, 2004; Cao, 2006; Gribkoff,
2006). The N-type Ca2+ channels control the release of glutamate and substance P at the
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pre-synaptic nerve terminals in the dorsal horn of the spinal cord (Smith et al., 2002),
thereby supporting pain transmission from the periphery to the CNS. Moreover,
engineered mice lacking N-type channels demonstrate decreased behavioral response to
neuropathic pain stimuli suggesting their role in nociception (Hatakeyama et al., 2001;
Saegusa et al., 2001). Recent studies have demonstrated the existence of multiple
isoforms of the N-type channel, derived from alternative splicing of N-type mRNA (Pan
and Lipscombe, 2000; Lin et al., 2004). Among the multiple isoforms, the e37a isoform
is markedly expressed in nociceptive DRG neurons and is specifically required for the
onset and maintenance of thermal and tactile hyperalgesia (Altier et al., 2007).
Neuromodulators/neurotransmitters

such

as

endogenous

opioids,

endo-

cannabinoids or GABA have been shown to regulate N-type calcium currents through G
protein-coupled receptor signaling (Holz et al., 1986; Polo-Parada and Pilar, 1999). Ntype channel inhibition occurs, in some cases, through direct interaction of the Gβγ
subunit with the intracellular loop between domains I and II (Figure 1) of the N-type α1
subunit (De Waard et al., 1997; Herlitze et al., 1997). Although the Gβγ subunits play a
primary role in N-type Ca2+ channel regulation, there is evidence to suggest that other
synapse associated proteins such as syntaxin1 may also regulate channel function
(Stanley and Mirotznik, 1997).
Unlike the HVA N-type channels, the LVA T-type Ca2+ channels regulate the
excitability of the sensory neurons (Catterall, 2000; Perez-Reyes, 2003) and play a key
role in the generation of acute peripheral nociceptive signals (Bourinet et al., 2005;
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Nelson and Todorovic, 2006). T-type channel modulation of neuronal activity results in
enhanced neurotransmission and amplification of sensory afferent signals, along with
increased pain perception (Perez-Reyes, 2003; Todorovic and Jevtovic-Todorovic, 2007).
There is increasing experimental evidence to support a role for T-type Ca2+ channels in
the development of neuropathic pain associated with peripheral nerve injury (Dogrul et
al., 2003) and, more recently, with painful diabetic neuropathy (Jagodic et al., 2007;
Messinger et al., 2009b).
T-type channels are typically resistant to modulation by conventional analgesic
compounds. However, recent molecular, genetic and electrophysiological studies have
described novel methods of T-type channel regulation that could have important
implications in neuropathic pain management. Specifically, T-type channels are regulated
by a number of cellular mechanisms including redox modulation. Reducing agents such
as dithiothreitol and L-cysteine (L-cys) selectively enhance LVA calcium currents in
small diameter DRG neurons. L-cys, DTT and other thiol containing L-cys analogs
produce hyperalgesia when experimentally introduced into peripheral receptive fields.
These agents are thought to sensitize C-type nociceptors that express T-type currents.
Furthermore, agents that are capable of chelating zinc ions mimic and occlude the effects
of L-cys and DTT whereas cysteine-modifying agents do not prevent the effects of
reducing agents on T-currents in DRG neurons. These effects can be completely
abolished by single-point mutations of histidine 191 to glutamine (H191Q) without
affecting channel kinetics (Zamponi et al., 2009). The H191Q mutation disrupts high-
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affinity zinc inhibition of CaV3.2 T-channel, suggesting that the effects of reducing
agents may occur indirectly by dis-inhibition of the channels endogenous zinc ions.
The CaV3.2 T-channel isoform that is predominately expressed in nociceptive
neurons is inhibited by the activation of G protein-coupled receptor signaling involving
selective interaction of Gβ2γ2 subunits to the channel α1 subunit (Wolfe et al., 2003; DePuy
et al., 2006). The CaV3.2 T-channel isoform has also been reported to be modulated by
various compounds such as nitrous oxide (Todorovic et al., 2001), phenytoin (Todorovic
and

Lingle,

1998),

certain

neuroactive

steroids

(Pathirathna

et

al.,

2005),

endocannabinoids (Ross et al., 2009) and by the actin binding protein, Kelch-like 1
(Aromolaran et al., 2010). The exact molecular determinants of the T-type channel that is
involved in this regulation is however, still unknown.

CHAPTER TWO
FORCED-EXERCISE ALLEVIATES NEUROPATHIC PAIN IN
EXPERIMENTAL DIABETES: EFFECTS ON VOLTAGE-GATED CALCIUM
CHANNELS

ABSTRACT
Exercise is now established as an integral adjunct to the management of diabetes.
Diabetic polyneuropathy, a painful complication of diabetes, remains untreatable,
emphasizing a critical need for improved therapeutic strategies. Recent evidence suggests
that exercise may facilitate recovery of peripheral nerve function in the diabetic
neuropathic patient. The mechanism by which exercise protects against peripheral nerve
dysfunction in diabetes is unknown, but may involve correction of glucose-associated
alterations of voltage-gated calcium currents (VGCC) in DRG neurons. Here, using a
combination of behavioral and patch clamp methodology, we examined the functional
consequences of exercise on VGCC in DRG neurons from streptozotocin (STZ)-induced
diabetic rats. Compared to vehicle control, STZ-treated sedentary rats developed marked
tactile hyperalgesia within two weeks of induction that was sustained for the 10-week
duration of study. STZ-treated rats subjected to forced-exercise (treadmill, 5.4 km/week),
by comparison, exhibited a significant delay in the onset of tactile hyperalgesia
independent of changes in blood glucose control. Addition of the non-selective opiate
receptor antagonist naloxone dose-dependently reversed the analgesic effect of forced46
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exercise in STZ-treated rats. Compared to sedentary vehicle-treated rats, the doseresponse to naloxone in exercised animals was rightward shifted. Small diameter DRG
neurons harvested from STZ-treated sedentary hyperalgesic rats exhibited a 2-fold
increase in peak high-voltage activated (HVA) calcium current density with a 10 mV
rightward shift; the low-voltage activated (LVA) calcium current component was
similarly enhanced 2-fold. Forced-exercise attenuated the diabetes-associated increase in
HVA peak current density. Moreover, the observed shift in HVA peak current density by
diabetes was normalized with forced-exercise. Steady-state inactivation (SSI) properties
of LVA calcium channels in DRG neurons from STZ-treated sedentary hyperalgesic rats
demonstrated a significant rightward shift (+8 mV; V50 = -50.9 ± 0.6 mV) that was
prevented by forced-exercise (V50 = -58.2 ± 1.4 mV; vehicle-treated control rats SSI V50
= -58.4 ± 0.9 mV). However, diabetes-associated increase in LVA current component
was unaffected by forced-exercise. These findings demonstrate that acute hyperglycemichypoinsulinemic insult elicits marked tactile hyperalgesia in the STZ-diabetic sedentary
rat by enhancing calcium influx in small diameter nociceptive DRG neurons. This may
occur, in part, by a mechanism that increases LVA calcium channel availability and
enhances both HVA and LVA Ca2+ channel currents. Forced-exercise was found to
significantly delay the onset of tactile hyperalgesia largely by preventing diabetesassociated changes in HVA and LVA channel functions.
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INTRODUCTION
Poorly controlled diabetes often leads to impaired function of central, peripheral,
and/or autonomic nerves (Emerick et al., 2005). As a result, nerve dysfunction associated
with diabetes is best realized clinically as a heterogeneous disease that encompasses a
wide range of neurologic abnormalities. Distal symmetrical polyneuropathy, the most
common form of diabetic polyneuropathy, is particularly debilitating, affecting both large
and small nerve fibers and altering a patient’s stability, sensorimotor function, gait, and
quality of life (Menz et al., 2004). The development of neuropathic pain including
hyperalgesia/allodynia, burning, tingling, and/or numbness sensations in a lengthdependent distribution, is prominent among diabetic patients and is strongly suggestive of
small nerve fiber impairment (Tavee and Zhou, 2009). Approximately a third of patients
with painful sensory neuropathy, and nearly half with otherwise idiopathic small fiber
neuropathy, experience some form of impaired glucose tolerance or metabolic
dysregulation (Singleton et al., 2001).
Lifestyle intervention designed to improve blood glucose control through weight
management with diet and exercise significantly reduced by 58% the incidence of type 2
diabetes in high risk patients (Knowler et al., 2002). In a small cohort of pre-diabetic
patients, Smith et al. (Smith et al., 2006) observed that lifestyle intervention similarly
improved impaired glucose tolerance with significant preservation of intra-epidermal
nerve fiber density, increased foot sweat volume (autonomic tone), and decreased
neuropathic pain. The cause of neuropathic pain associated with impaired glucose
tolerance, or with frank diabetes, remains unclear. Early experimental studies suggest that
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intermittent hyperglycemia damages sensory neurons and increases spontaneous C-fiber
firing, resulting in neuropathic pain (Chen and Levine, 2001).
The analgesic effect of exercise has been previously reported (Willow et al., 1980;
Janal, 1996; O'Connor and Cook, 1999). Rats subjected to swimming exercise,
demonstrate an attenuated response to inflammatory neuropathic pain (Kuphal et al.,
2007). Mice subjected to treadmill running exhibited increased tail flick latencies to a
heat stimulus (Blustein et al., 2006). Evidence supporting a protective effect of moderate
aerobic exercise against the development of neuropathic complications in diabetic
patients is mounting (Balducci et al., 2006), raising interest in aerobic exercise as a
putative therapeutic intervention for the management of painful diabetic neuropathy. In a
preliminary study, (Fisher et al., 2007) report that aerobic exercise statistically improves
some measures of peripheral nerve function in diabetic patients with established lengthdependent neuropathy.
The cellular mechanism(s) by which neuropathic pain develops in the diabetic
patient is poorly understood, but may involve remodeling of voltage- or ligand-gated ion
channels (Carbone and Lux, 1984; Nowycky et al., 1985; Cao, 2006) leading to abnormal
enhancement of sensory neuron excitability (Ikeda and Dunlap, 2007). Voltage gated Nand T-type Ca2+ channels are established mediators of pain signaling and processing in
afferent neurons (Zamponi et al., 2009). N-type Ca2+ channels are activated by large
changes in membrane potential and regulate neurotransmitter release. By comparison, Ttype Ca2+ channels are activated by small changes in membrane potential, thereby
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regulating the excitability of the sensory neuron (Catterall, 2000; Perez-Reyes, 2003) and
playing a key role in the generation of acute peripheral nociceptive signals (Bourinet et
al., 2005; Nelson and Todorovic, 2006). There is increasing experimental evidence to
support a role for T-type Ca2+ channels in the development of neuropathic pain associated
with peripheral nerve injury (Dogrul et al., 2003) and, more recently, with painful
diabetic neuropathy (Jagodic et al., 2007; Messinger et al., 2009b).
Given the potential application of moderate intensity exercise to be of therapeutic
value for the management of painful nerve dysfunction in patients with DM, we
investigated in this study the consequence of forced-exercise on voltage gated Ca2+
channel function in nociceptive (small-diameter) DRG neurons from streptozotocininduced hyperalgesic rats. A preliminary account of these findings have been previously
reported (Shankarappa et al., 2007; Shankarappa et al., 2009). The present chapter
addresses the proposed first and second specific aims of this dissertation.
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MATERIALS AND METHODS

Animal care
This study was conducted using protocols approved by the Edward Hines Jr. VA
Hospital Institutional Animal Care and Use Committee in accordance with the principles
of laboratory animal care (National Institutes of Health Publ. 86-23, 1985). All animals
were housed in pairs, allowed standard rat diet and water ad libitum, and maintained on a
10h/14h light/dark cycle. Adult male Sprague-Dawley rats (initial body weight 200 g)
were randomly divided into two treatment groups (vehicle-control or STZ-induced
diabetes) and a subset of each group subjected to daily 1h-sessions of either exercise or
sedentary inactivity for up to 10 weeks.
Induction of experimental diabetes mellitus
Streptozotocin (STZ) was used in this study to induce experimental DM, a well
established animal model of painful diabetic neuropathy. Non-fasted ketamine (100
mg/kg)-xylazine (5 mg/kg) anesthetized rats received a single intraperitoneal injection of
freshly prepared streptozotocin (STZ, 60 mg/kg body wt; Sigma-Aldrich, St. Louis, MO)
dissolved in citrate buffer (100 mmol/l; pH 4.5). Non-diabetic control, gender and agematched rats received an equal volume of intraperitoneally injected, freshly prepared
citrate buffer (100 mmol/l; pH 4.5). Non-fasting blood glucose levels were determined
before vehicle or STZ was administered and at regular weekly intervals throughout the
study. Blood samples were obtained by tail prick, and glucose content was quantified
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using a calibrated commercial glucometer (MediSense Precision QID glucometer, Abbot
Laboratories, Bedford, MA). STZ-treated rats exhibiting blood glucose levels <300 mg/dl
(<16.6 mmol/L) at 48h post treatment were considered to be non-diabetic and were
excluded from further study. Animals were weighed daily to monitor disease progression
and severity.
Experimental exercise regimens
Experimentally, there are two categories of exercise regimens that can be utilized
to study the effect of exercise. Animals can be subjected to either a voluntary or forced
exercise regimen. To determine the optimal exercise regimen for this study, rats were
assigned either to the forced-exercise or the voluntary running groups.
Voluntary-exercise: In the voluntary running group, rats were housed individually at
night, for 16h (5 Pm to 9 Am) in an enclosed glass chamber (11.5 X 14.2 X 7.5, inches)
with a running wheel (37 inches in circumference) fitted with a standard cyclometer.
Animals had unrestricted access to food and water within the glass chamber. Rats were
allowed to explore and adapt to the running wheel for 2 weeks prior to STZ treatment.
Upon STZ treatment, rats were allowed to run 5 nights a week for a period of 4 weeks.
Distance run was recorded daily. Animals were returned to their home cages every
morning.
Forced-exercise: Prior to vehicle- or STZ-treatment, rats assigned to the forced-exercise
group were acclimated (5-day training period) to a motorized treadmill (Exer 3/6 Open
treadmill, Columbus Instruments, Columbus, OH) equipped with a motivational shock
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grid set to emit an innocuous 8mA electric shock to the plantar surface. Training involved
a gradual transition at zero grade inclination toward a constant velocity (18 m/min) and
duration (60 min/day). On the fifth day, after training, rats received either vehicle- or
STZ-treatment. Rats were run between 9:00h-13:00h for 60 min/day x 5 days a week for
10 weeks. Rats subjected to this regimen showed no evidence of foot trauma or callus
formation. Vehicle- or STZ-treated rats assigned to the sedentary groups were allowed to
explore an identical sized environment for the same duration of time (including the
training period), but without receiving an exercise challenge or shock incentive.
Tactile-responsiveness to Von-Frey filaments
Tactile responsiveness was measured separately on all animals at 0-, 2-, 4-, 6-, 8-,
and 10-weeks post vehicle- or STZ-treatment. Tactile responsiveness was measured using
logarithmically calibrated Semmes Weinstein monofilaments (Stoelting Co, Wood Dale,
IL) and semi-quantified by the Up-Down method of Dixon as previously described
(Chaplan et al., 1994). Following acclimation to a wire mesh bottom, the mid plantar
surface of both hind feet of each rat were separately probed at right angle for 8s with
sufficient force to cause slight buckling of the monofilament. Paw withdrawal occurring
within the 8s stimulus duration was considered a positive response. Testing began with a
2g-force equivalent monofilament followed by hairs with greater or lesser mass-force
depending on the previous paw response. In the event of a positive paw withdrawal to the
initially selected filament, the next lesser mass-force filament was presented. Similarly, in
the event of an absent paw withdrawal response, the next higher mass-force filament was
presented. A total of six consecutive critical data points were considered starting from
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one data point prior to the first positive withdrawal response. The withdrawal threshold,
defined as the filament mass-force (grams) required to elicit a 50% response rate, was
calculated using the formula (Chaplan et al., 1994):

where x = the value of the last filament used, in log units, k = a tabular value for the
pattern of positive and negative response generated and δ = the mean mass-force
difference (log units) between filaments (0.224). Recordings were repeated twice per
animal and the mean considered as the withdrawal threshold. Thresholds generated in this
manner were considered to have a non-parametric distribution.
In a separate experiment, the role of opioids in mediating forced-exercise induced
affect on diabetes-associated tactile hyperalgesia was determined. Tactile responsiveness
was measured in 2 week post veh- or STZ- treated rats, subjected to either forcedexercise or sedentary regimens. Prior to withdrawal threshold testing, rats received 0, 5 or
10 mg/kg of naloxone (Sigma, St Louis, MO), administered via the intraperitoneal route.
Saline was used as vehicle. Withdrawal threshold recordings were performed 8 minutes
after naloxone administration.
Thermal responsiveness to infra-red heat stimulus
Thermal responsiveness was quantified using a microprocessor-controlled
infrared Ugo Basile Thermal Plantar Analgesia Instrument (Stoelting Co, Wood Dale,
IL). Briefly, rats placed on a temperature-controlled (23-24°C) glass platform were
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allowed to acclimate x 30 min. After the acclimation period, the infrared lamp with a preset intensity (Figure 6C) was positioned directly beneath the rat’s hindpaw and manually
activated. Upon paw withdrawal, latencies were automatically recorded to the nearest
0.1s. Mean of three trials was considered as the withdrawal latency.
Peripheral nerve conduction studies
Evoked compound muscle action potential (CMAP) amplitudes and latencies of
peripheral nerves were quantified at week 0 and again at week 8 post vehicle- or STZtreatment as previously described (Lawlor et al., 2002). Briefly, sciatic nerves of
ketamine (100 mg/kg)-xylazine (5 mg/kg) anesthetized rats were stimulated at the sciatic
notch or at the ankle (tibial nerve) with unipolar pin electrodes using supramaximal
stimuli (25 mA, 0.05-ms duration) at high frequency (1 Hz) for the direct measurement of
motor nerve (M-wave) responses (Figure 2). Unipolar pin recording electrodes were used
to record the evoked potentials from the plantar muscles of the left hind foot. Individual
responses were amplified and recorded using a TECA Synergy electromyograph system.
For each animal, the M-wave was measured as an average of 25 individual evoked
responses, repeated in triplicate. Motor nerve conduction velocity was calculated as the
distance from notch-to-ankle divided by the difference of the M-wave latency (notch–
ankle). A heating pad was used to maintain the body temperature of the rat at 37°C.
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Figure 2. Evoked compound muscle action potential recording from the rat sciatic
nerve

For recording sensory nerve conduction velocity (SNCV), the tail nerve was
stimulated (6 mA, 0.01 ms) 6 cm and 10 cm distal to the recording ring electrode with
unipolar pin electrodes. The recording ring electrode was placed at the base of the tail,
with the reference electrode placed 1cm proximal to the recording electrode. A series of
8 individual responses were evoked at a frequency of 1 Hz, with each series being
repeated three times. SNCV was calculated as the distance between the proximal and the
distal stimulation points (4 cm) on the tail divided by the difference in nerve action
potential latency.
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Dissociation of dorsal root ganglia neurons
Vehicle- or STZ-treated rats were euthanized by CO2 asphyxiation, a lumbar
laminectomy was performed, and lumbar (L4-L5) dorsal root ganglia were extracted and
quickly immersed in ice-cold Ca2+ and Mg2+ free Hank’s Balanced Salt Solution (HBSS,
Invitrogen, Carlsbad, CA). DRG neurons were isolated using a modified procedure,
based on a previously reported method (Scroggs and Fox, 1992). Briefly, DRG neurons
were prepared by dissociation at 37ºC x 30min in the presence of collagenase (2 mg/ml;
type I, Sigma-Aldrich, St. Louis, MO) and dispase (5 mg/ml; type II, Invitrogen,
Carlsbad, CA). Dissociated DRG neurons were washed in HBSS supplemented with 20%
fetal bovine serum (FBS, Invitrogen, Carlsbad, CA) and subsequently plated on uncoated
glass coverslips in preparation for whole-cell voltage-clamp recordings as previously
described (Aromolaran et al., 2007). Small, medium, and large diameter DRG neurons
were typically present in our dissociated preparations (Figure 8). Since neuropathic pain
transmission is largely facilitated by small-diameter DRG neurons, only cells with soma
diameters less than 30 m (i.e., <30pF) were patched. In all cases, dissociated small
diameter DRG neurons were used within 6 h of harvest.
Voltage clamp electrophysiology
Ca2+ currents were recorded in acutely dissociated small diameter DRG neurons
lacking visible processes. Soma were continuously perfused with an external solution
(300 mOsm) containing (mM): 2 CaCl2, 140 tetraethylammonium (TEA)-Cl, 10 HEPES
(pH 7.4), and 10 glucose (Aromolaran et al., 2007). Electrodes were pulled from
borosilicate glass microcapillary tubes (Warner Instruments, LLC, Hamden, CT) and had
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a resistance from 2-4 MΩ when filled with an internal solution (280 mOsm) containing
(mM): 108 CsMeSO3, 4 MgCl2, 1 Cs-EGTA, 9 HEPES (pH 7.4), 5 ATP-Mg, 1 GTP-Li,
15 phosphocreatine-TRIS. Whole-cell somatic Ca2+ currents were recorded using an
Axopatch 200B patch-clamp amplifier (Molecular Devices, Palo Alto, CA) at 23 ºC and
digitized using a Digidata 1322A converter interfaced with pClamp Software. Cell
capacitance was measured from a transient current evoked by a 5 mV depolarizing pulse
from a holding potential (Vh) of -90 mV. Currents were low-pass filtered at 1 kHz. Series
resistance and capacitance values were obtained after electronic subtraction of capacitive
transients. Voltage clamp recordings were obtained by patching small diameter DRG
neurons with uncompensated series resistance of <20 MΩ and cell capacitance <30 pF
(Table 2). LVA and HVA currents were elicited from Vh = -90mV. HVA currents were
recorded in isolation from LVA currents using Vh = -50mV, a voltage that completely
inactivates LVA currents (Carbone and Lux, 1984; Bean, 1992). In each case, soma were
depolarized for 250 ms to test potentials (Vt) = -80 to +50 mV, with 10 mV increments.
The net LVA current contribution was determined by using current subtraction at
different Vh (Fig. 4B). Currents recorded from Vh = -50mV were subtracted from those
obtained using Vh = - 90mV for each Vt from -70mV to -20mV as previously described
(Xu and Best, 1992). Steady-state inactivation (SSI) of LVA Ca2+ channels was assessed
using an established double-pulse protocol. DRG neurons held at -90mV received a series
of pre-conditioning pulses (-110mV to +10mV; 10 mV increments, 1.5s duration)
followed by a depolarizing test pulse to -30mV in order to evoke Ca2+ channel opening
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(Aromolaran et al., 2007). Data were analyzed by Clampfit (Molecular Devices) and
fitted to a single Boltzmann distribution

where Imax is the maximal current amplitude, V50 is the voltage at which half of the
current is inactivated, k is the voltage dependence (slope) of the function.
Statistical analysis
Data are expressed as the mean ± SEM of N observations unless noted otherwise.
Statistical significance between multiple experimental groups was determined by oneway or two-way ANOVA with a Bonferroni multiple comparison post-hoc analysis. In
each case, p < 0.05 was considered statistically significant.
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RESULTS
Streptozotocin-induced diabetes and voluntary-exercise
Rats given access to voluntary running wheels ran ~ 0.6 Km/night (16h, 16:00 to
09:00) prior to vehicle or STZ administration (Figure 3). Upon STZ-treatment, the
average daily running distance gradually decreased over the study period. At the end of 4
weeks, STZ-treated rats ran 0.09 ± 0.01 Km/night as compared to the vehicle-treated rats
which maintained a running distance of 0.5 ± 0.04 Km/night. This decreased voluntary
running behavior of STZ-diabetic rats lead us to adopt forced treadmilling as the exercise
intervention of choice.
Streptozotocin-induced diabetes and forced-exercise
Administration of freshly prepared streptozotocin (STZ) to adult male SD rats
produced a marked elevation of non-fasting blood glucose levels (>16.7 mmol/L) that
was sustained throughout this 10-week study (Figure 4A). Rats forced to run
continuously on a zero grade treadmill (forced-exercise; 18m/min x 60min/day for 5
days/week) exhibited nearly identical sustained increases in blood glucose (Figure 4A).
Previously, we demonstrated that subcutaneous implantation of insulin pellets at 4 weeks
reversed the observed hyperglycemic effects of STZ and normalized blood glucose levels
to near physiological concentrations in sedentary SD rats (Emerick et al., 2005),
consistent with the experimental induction of insulin-dependent DM. By comparison,
control rats receiving an equal volume of citrate buffer (100 mmol/L; pH 4.5) maintained
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non-fasting blood glucose levels near 6 mmol/L (Figure 4A). Blood glucose levels were
similarly unaffected by continuous forced-exercise in vehicle-treated control rats.
The body weights of the vehicle-treated (non-diabetic) rats steadily increased over
the course of study (Figure 4B). By comparison, STZ-induced diabetic rats exhibited a
steady decline in the rate of body weight gain. Vehicle-treated rats undergoing
continuous forced-exercise exhibited a delay in the rate of body weight gain resulting in
20-25% less overall weight gain. A similar, but more exaggerated delay was observed
with STZ-induced diabetic rats undergoing forced-exercise (Figure 4B). At no time
throughout the course of this study, did sedentary or forced-exercises STZ-induced
diabetic rats lose body weight, suggesting that complications secondary to diabetesinduced cachexia was negligible.
Forced-exercise protects against STZ-induced diabetes-associated nerve conduction
deficits
We next determined the effect of forced-exercise on peripheral nerve function in
vehicle- and STZ-treated rats by evoked-response electrophysiology (Emerick et al.,
2005; Sarkey et al., 2007). Despite exhibiting marked and sustained hyperglycemia, STZtreated rats (8-weeks) maintained near normal evoke-response sciatic/tibial nerve
conduction amplitudes when compared with vehicle-treated non-diabetic controls or pretreatment (baseline) measures (Table 7). In contrast, calculated motor nerve conduction
velocities (MNCV) in STZ-treated (8-weeks) rats were slowed by approximately 23%,
consistent with previous reports (Manschot et al., 2003). Forced-exercise did not alter the
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calculated MNCV in vehicle-treated non-diabetic rats when compared with sedentary
vehicle-treated non-diabetic rats (Table 7). By comparison, calculated MNCV in STZtreated rats undergoing forced-exercise were statistically indistinguishable from vehicletreated forced-exercise non-diabetic control rats or pre-treatment (baseline) measures
(Table 7).
SNCV (32.4 ± 1.3 m/s), recorded from the tail nerve of STZ-treated rats was not
however significantly different from vehicle treated controls (35 ± 3 m/s) (Table 8).
Similarly, forced-exercise did not affect SNCV in vehicle- (30.0 ± 0.5 m/s) or STZtreated rats (31.5 ± 1.3 m/s) (Table 8). These data suggest that, unlike the sciatic nerve,
the tail nerve is spared from STZ-induced diabetes associated conduction deficits.
Forced-exercise delays onset of diabetes-associated hyperalgesia
To assess whether forced-exercise alters STZ-induced diabetes-associated
nociception in vivo, we determined behavior response thresholds to tactile and thermal
stimuli as a function of time (0-10 weeks). Vehicle-treated sedentary non-diabetic rats
exhibited tactile withdrawal threshold sensitivities of 12.8 ± 0.6 g (n = 8) that were
maintained over the 10-week course of study (Figure 5A). Forced-exercise vehicletreated rats responded similarly to tactile stimulation, suggesting that the forced-exercise
regimen used in this study does not significantly alter tactile sensitivity. Within 2-weeks,
STZ-treated hyperglycemic sedentary rats developed an enhanced sensitivity to tactile
stimuli that was sustained throughout the 10-week course of study (Figure 5B). This is
consistent with the development of neuropathic hyperalgesia/allodynia in STZ-treated
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rats as previously reported (Malcangio and Tomlinson, 1998). By comparison, forcedexercise significantly (p<0.05) delayed by approximately 4-weeks the onset of tactile
hyperalgesia in STZ-treated hyperglycemic rats (Figure 5B) without altering blood
glucose levels (Figure 4A). Moreover, statistical evaluation between sedentary and
forced-exercise STZ-treated rats by two-way ANOVA found that the treatment-time
interaction was highly significant (F(5, 72) = 6.21, p<0.0001).
Responsiveness to thermal stimulus is not altered by forced-exercise
To assess whether forced-exercise similarly affects thermal responsiveness,
thermal withdrawal latencies were determined using a modified Hargreaves method
(Hargreaves et al., 1988) in response to a infrared heat source of specified intensity
(Figure 6C). Thermal withdrawal latencies (10.9 ± 0.5s, n = 22) obtained from naïve
euglycemic rats were not significantly different from those of vehicle-treated sedentary
non-diabetic rats (10.1 ± 0.5s, n = 4; 10-weeks) (Figure 6A). A significant, but modest,
reduction in thermal withdrawal latency (8.3 ± 0.1s, n = 7; 10-weeks,) was seen in STZtreated hyperglycemic rats (Figure 6B). Earlier timed points (2, 4, 6, and 8-weeks),
however, were not statistically different from vehicle-treated controls. Ten-weeks of
forced-exercise did not alter thermal withdrawal latencies in vehicle-treated control rats
(12.0 ± 1.2s, n = 4). STZ-treated hyperglycemic rats undergoing 10-weeks of forcedexercise had thermal withdrawal latencies (10.5 ± 1.0s, n = 7) that were statistically
indistinguishable (p = 0.3) from vehicle or naïve control values.
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Naloxone reverses forced-exercise induced analgesia
To determine the mechanism by which forced-exercise protects against the
development of diabetes-associated tactile hyperalgesia, we assessed hind-paw
withdrawal thresholds after administration of naloxone hydrochloride, a non-selective
opiate receptor antagonist. In vehicle-treated sedentary rats, naloxone reduced hind-paw
withdrawal thresholds in a dose-dependent manner (Fig. 6.). Naloxone (5 mg/kg) in
vehicle-treated sedentary rats decreased the mean withdrawal threshold to 3.3 ± 1.3 g. In
contrast, exercised vehicle-treated animals demonstrated a significant rightward shift in
the naloxone dose-response curve (11.0 ± 1.9 g in response to 5 mg/kg naloxone). This
data suggests the presence of increased endogenous opioids in non-diabetic vehicletreated rats subjected to forced-exercise. In comparison, STZ-treated exercised rats
exhibited a similar dose-response profile (10.4 ± 2.0 g in response to 5 mg/kg naloxone)
as the exercised vehicle-treated group. Both, vehicle- and STZ-treated exercised groups
demonstrated reduced withdrawal thresholds with 10 mg/kg naloxone (veh-exe: 3.1 ± 0.7
g and STZ-exe: 4.1 ± 0.2 g). STZ-treated sedentary rats exhibited a withdrawal threshold
of 3.3 ± 0.4 g, and were not challenged with naloxone.
Forced-exercise prevents diabetes associated alteration in Ca2+ current densities
To determine the mechanism by which forced-exercise protects against the early
development of tactile hyperalgesia in STZ-induced diabetic rats, we measured Ca2+
current densities in small diameter (21.4 ± 0.9 m) DRG neurons (Figure 8A) harvested
from vehicle- or STZ-treated sedentary or STZ-treated force-exercised rats. Confirmation
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of tactile responsiveness was determined in all rats prior to tissue harvest and voltageclamp analysis. DRG neurons have been previously reported to co-express several types
of Ca2+ channels, including low-voltage activated (LVA) T-type and high-voltage
activated (HVA) N-, L-, and P/Q-Type channels (Scroggs and Fox, 1992). Passive
membrane properties between voltage-clamped DRG neurons harvested from vehicle,
STZ, and forced-exercise STZ groups were not significantly different (Table 9). Inward
Ca2+ currents elicited from a Vh = -50 mV (Vt = 0 mV) exhibited prolonged inactivation
characteristic of HVA currents (Figure 9A). DRG neurons from vehicle-treated sedentary
rats exhibited HVA Ca2+ currents that peaked at 0 mV, with a maximum current density
of -8.2 ± 1.0 pA/pF (Figure 9B). DRG neurons from STZ-treated sedentary hyperalgesic
rats, by comparison, demonstrated significant enhancement (>2.5-fold) of HVA Ca2+
current density whose peak (-26.3 ± 2.8 pA/pF) was rightward shifted to +10 mV (Figure
9B). In contrast, DRG neurons from STZ-treated rats undergoing forced-exercise
displayed HVA Ca2+ currents with an intermediate density (-16.8 ± 2.3 pA/pF) that
peaked at 0 mV, identical to sedentary vehicle controls. Moreover, current-voltage curves
obtained from DRG neurons of sedentary or forced-exercise diabetic rats exhibited an
atypical shoulder near -30 mV (Figure 9B) that is suggestive of the emergence of LVA Ttype Ca2+ currents in these neurons.
Inward Ca2+ currents elicited from a Vh = -90 mV exhibited rapid (~100 ms)
inactivation properties consistent with the presence of LVA ‘T-type’ currents in diabetic
DRG neurons (Figure 10A). Compared to HVA currents, the peak density of the
observed LVA component was modest, as expected for these currents. However, at a Vt =
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-30mV, peak LVA Ca2+ current density in diabetic DRG neurons was enhanced
approximately 2-fold compared to vehicle controls (Figure 10B). In contrast to HVA
currents, however, forced-exercise did not alter diabetes-associated increases in LVA
Ca2+ current density (Fig. 4B) or the net LVA Ca2+ current component (Figure 10C).
Diabetes-associated changes in LVA Ca2+ current steady-state inactivation
The presence of LVA currents elicited from Vh = -50mV (Figure 11A) indicates
altered voltage-dependent inactivation properties. As shown in Figure 11, steady-state
inactivation (SSI) properties of LVA Ca2+ currents in DRG neurons from STZ-treated
diabetic rats exhibited a significant (p<0.05) rightward depolarizing shift (7.5 mV; V50 =
-50.9 ± 0.6 mV) that occurred in parallel with the early development of tactile
hyperalgesia. In contrast, LVA Ca2+ currents in neurons from forced-exercised STZtreated rats displayed V50 values that were indistinguishable (V50 = -58.2 ± 1.4 mV) from
vehicle-treated controls (V50 = -58.4 ± 0.9 mV). The slope (k) of the SSI curves did not
differ significantly among vehicle (-7.5 ± 0.8), sedentary STZ (-6.1 ± 0.6), or forcedexercise STZ-treated (-7.3 ± 1.2) groups.
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Figure 3. Effect of STZ-treatment on voluntary wheel running in SD rats.
Comparative changes in nocturnal running distance (Kms) in vehicle-treated rats (open
circles, n=3), compared to STZ-treated rats (closed circles, n=3). Animals were given
access to running wheels starting one week prior to vehicle or STZ administration. Data
shown are means ± SEM.
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Figure 4. Effect of forced-exercise on progression of experimental diabetes.
Comparative changes in (A) blood glucose concentration and (B) body weight gain
(expressed as a percentage of initial body weight) in vehicle- (circles) and STZ-treated
(squares) sedentary (open symbols) or forced-exercise (closed symbols) rats. Data shown
are the means ± SEM (vehicle, n=4; STZ, n=7).
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Figure 5. Effect of forced-exercise on the onset and progression of tactile
hypersensitivity in STZ-treated rats.

Withdrawal thresholds to von Frey filaments in (A) vehicle- (circles) or (B) STZ-treated
(squares) sedentary (open symbols) or forced-exercise (closed symbols) rats. Data shown
are the means ± SEM (vehicle, n=4; STZ, n=7). *, p < 0.05; two-way repeated measures
ANOVA with post-hoc Bonferonni multiple comparison analysis.
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Figure 6. Effect of forced-exercise on thermal responsiveness in STZ-treated rats.
Hind-paw withdrawal latency from (A) vehicle-(circles) or (B) STZ-treated (squares)
sedentary (open symbols) or forced-exercised (closed symbols) rats are shown. Data
shown are the means ± SEM (vehicle, n=4; STZ, n=7). (C) Rate of change in thermal
intensity (°C) from the infra-red lamp used to measure withdrawal latency in (A) and (B).
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CMAP Amplitude
(mV)

Baseline
Notch
Ankle
Notch/Ankle Ratio
8-week
Notch
Ankle
Notch/Ankle Ratio

Sedentary

Forced-Exercise
Vehicle
STZ

Vehicle

STZ

2.2 ± 0.4
3.3 ± 0.3
0.7

3.9 ± 0.5
4.5 ± 0.3
0.9

4.2 ± 0.5
4.9 ± 0.3
0.9

3.1 ± 0.3
4.1 ± 0.3
0.8

5.2 ± 1.2
6.5 ± 1.1
0.8

3.6 ± 0.7
4.9 ± 0.8
0.7

4.6 ± 0.4
5.5 ± 0.4
0.8

3.4 ± 0.2
4.6 ± 0.5
0.7

Sedentary

Forced-Exercise

Conduction
Velocity (m/s)

Vehicle

STZ

Vehicle

STZ

Baseline

44.4 ± 3.5

53.5 ± 4.1

45.0 ± 3.3

46.1 ± 2.4

8-week

50.9 ± 1.9

41.3 ± 3.1*

53.1 ± 5.3

51.0 ± 1.3

Table 7. Evoked compound muscle action potential response from the sciatic nerve of
STZ-diabetic rats subjected to sedentary or forced-exercise.

Compound muscle action potential amplitudes and conduction velocity were evoked and
quantified at baseline (week 0) and again at week 8 from vehicle (n = 4)- or STZ (n = 7) treated rats subjected to a sedentary or forced-exercise regimen as described in methods.
Data shown are the means ± SEM; *, p<0.05 Student’s t-test.
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Conduction
Velocity (m/s)

Vehicle

STZ

Baseline

25.0 ± 0.7

23.3 ± 0.8

21.6 ± 0.3

25.4 ± 1.2

8-week

30.5 ± 1.3

32.4 ± 1.3

30.0 ± 0.5

31.5 ± 1.3

Sedentary

Forced-Exercise
Vehicle
STZ

Table 8. Conduction velocity calculated from the tail nerve in diabetic rats subjected to
forced-exercise.
Tail nerve action potential were evoked and conduction velocity calculated at baseline
(week 0) and again at week 8 from vehicle (n = 4) - or STZ (n = 8) -treated rats subjected
to a sedentary or forced-exercise regimen as described in methods. Data shown are the
means ± SEM.
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Figure 7. Effect of naloxone on forced-exercise induced analgesia.
Hind-paw withdrawal threshold from vehicle- (open symbols) and STZ- (closed symbols)
treated forced exercise (square) and sedentary (circles) rats. Data are mean ± SEM of (4)
observations per group. *, p < 0.05; One way ANOVA.
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Figure 8. Percentage of small, medium and large diameter DRG neurons harvested
from naïve adult rat.
Dissociated DRG neurons were classified into small, medium and large cells based on
their cellular diameter as described in methods (A) Dissociated small diameter DRG
neurons and (B) Box and whisker plot showing the percentage size distribution of
neurons in the DRG.
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Figure 9. Forced-exercise attenuates diabetes-associated enhancement of HVA Ca2+
current density in dissociated small diameter DRG neurons.
(A) Representative current tracings elicited from a holding potential of -50mV to peak
test pulses. (B) Current-voltage curves from sedentary vehicle-treated (open circles, n=9),
STZ-treated (closed circles, n=15), or forced-exercise STZ-treated (closed squares, n=6)
rats. Currents shown are normalized to cell size (capacitance) and are expressed as the
means ± SEM. (C) Quantitative comparison of peak current density between sedentary
vehicle (veh), streptozotocin (STZ), and forced-exercised streptozotocin-treated (STZ +
Exe) rats. Data shown are means ± SEM of N observations indicated in (B). *, p<0.05;
one-way ANOVA with post-hoc Bonferonni multiple comparison analysis.
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Figure 10. Effect of forced-exercise on LVA Ca2+ current density in dissociated small
diameter DRG neurons.
(A) Representative current tracings elicited from a holding potential of -90mV at a test
pulse of -30 mV. (B) Current-voltage curve from sedentary vehicle-treated (open circles,
n=8), STZ-treated (closed circles, n=17), or forced-exercise STZ-treated (closed squares,
n=7) rats. Currents shown are normalized to cell size (capacitance) and are expressed as
the means ± SEM. (C) Net LVA Ca2+ current components obtained by trace subtraction
of currents shown in Figure 9 from Vt = -70mV to -20mV.
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Figure 11. Forced-exercise prevents diabetes-associated increase in LVA Ca2+ channel
availability.
(A) Steady-state inactivation of LVA Ca2+ channels in small diameter DRG neurons from
sedentary vehicle-treated (open circles, n=6), STZ-treated (closed circles, n=6), and
forced-exercise STZ-treated (closed squares, n=5) rats. (B) Quantitative comparison of
V50 values derived from A. Data shown are the means of N observations. *, p<0.05; oneway ANOVA with post-hoc Bonferonni multiple comparison analysis.
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DRG Source
Sedentary Vehicle (9)
Sedentary STZ (14)
Force-Exercise STZ (7)

Series Resistance (M )

Capacitance (pF)

17.5 ± 2.6

20.0 ± 2.2

13.0 ± 1.7

17.1 ± 1.4

10.3 ± 1.1

15.6 ± 1.1

Table 9. Passive membrane properties of dissociated small diameter DRG neurons.
Data shown are the means ± SEM from (N) DRG neurons harvested from sedentary
vehicle-, sedentary STZ-, or force-exercised STZ-treated rats.
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DISCUSSION
This is the first study to demonstrate that forced-exercise markedly delays the
onset of tactile hyperalgesia, a semi-quantitative behavioral measure of painful
neuropathy, in experimentally-induced diabetic rats. The protective effects of forcedexercise occurred independent of blood glucose control. Diabetes-associated changes in
HVA Ca2+ current density in small-diameter dorsal root ganglia (DRG) sensory neurons
were significantly attenuated by forced exercise. Steady-state inactivation (SSI, a
measure of channel availability and an indicator of neuronal excitability) of LVA Ca2+
channels in diabetic DRG neurons revealed a significant depolarizing (sensitizing) shift
that was prevented by forced-exercise. We propose that forced-exercise delays the
development of painful neuropathy in experimental diabetes, in part, by preventing
diabetes-associated remodeling/modulation of Ca2+ channels in DRG sensory neurons.
Painful diabetic polyneuropathy is untreatable in humans. Current management of
affected patients primarily involves alleviation of discomfort and glycemic control
(DCCT, 1993). Early clinical studies reveal a significant independent association between
the occurrence of diabetic complications, including neuropathy, and declining exercise
capacity among diabetic patients (Estacio et al., 1998). The application of exercise has
since then been established as a safe and effective integral approach to the management
of diabetes (Lynch et al., 1996; Knowler et al., 2002). The question of whether exercise
protects against the development and progression of diabetic neuropathic complications,
however, remains unresolved. Recent preliminary studies with small cohorts of
neuropathic diabetic patients support a beneficial effect of exercise on some measures of
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peripheral nerve function (Richardson et al., 2001; Fisher et al., 2007). Exercise
(Balducci et al., 2006), or lifestyle intervention strategies that include an exercise
component (Smith et al., 2006), may even delay or protect against the development of
diabetic peripheral nerve complications.
It is well established that the peripheral nerve damage develops in diabetes in
close association with poorly-controlled chronic hyperglycemia. Numerous thesis have
been proposed to explain the association between prolonged hyperglycemia and nerve
dysfunction, including alterations in voltage-gated ion channel function (Tomlinson and
Gardiner, 2008). Sustained periods of hyperglycemia are reported to reduce nodal Nav1.6
peak current density in myelinated neurons (Wittmack et al., 2005), possibly contributing
to well described diabetes-associated deficits in nerve conduction velocity (Table 1). By
comparison, acute periods of hyperglycemia may precipitate neuropathic pain. Pain
thresholds are markedly decreased following glucose administration to healthy volunteers
(Morley et al., 1984) and to experimental animals (Lee et al., 1990). Moreover, direct
application of hyperglycemic solutions to DRG neurons in vivo reduces mechanical pain
thresholds (Dobretsov et al., 2001). In this study, we found that an acute period (2-week)
of sustained hyperglycemia/hypoinsulinemia precipitated a selective hypersensitivity to
mechanical stimuli (defined here as tactile hyperalgesia). In marked contrast, diabetic rats
undergoing forced-exercise exhibited normal sensitivity to tactile stimuli despite elevated
levels of blood glucose. The protective effect of forced-exercise was transient, however,
with diabetic rats developing tactile hyperalgesia by the sixth week of sustained
hyperglycemia/hypoinsulinemia. The mechanism by which forced-exercise delays the
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development of tactile hyperalgesia was unrelated to glycemic control. Insulin content,
while not measured in this study, was not expected to change with forced exercise in
STZ-treated animals (Howarth et al., 2009), since blood glycemic index, which is a
reflection of insulin activity remained unchanged in both groups.
Previous studies have suggested the role of altered opioid-mediated analgesia in
diabetes (Simon and Dewey, 1981; Kamei et al., 1992). Reduced potency of morphine
(Chen and Pan, 2003), and decreased endogenous opioid levels in diabetic animals
(Williams et al., 2008) are thought to contribute towards a lowered opioidergic tone,
resulting in an enhanced pain state. Opioid receptor expression and receptor binding in
neurons from the dorsal horn and the DRG of diabetic animals remain unchanged (Hall et
al., 2001; Chen and Pan, 2003). In this study, naloxone reversed the analgesic effect of
forced-exercise in diabetic animals and showed similar elevation of pain thresholds in
both, vehicle- and STZ- treated forced-exercised animals. This observation may be due to
exercise induced increase in endogenous opioids. Exercise mediated increase in pain
threshold due to enhanced release of endogenous opioids is well documented in both
human and animal studies (Koltyn, 2000). Alternatively, previous studies also indicate,
that exercise-facilitated neuroprotection may be mediated by changes in neurotrophic
support (Hutchinson et al., 2004).
A slowing of nerve conduction velocity is a well established feature of diabetic
neuropathy (Greene et al., 1999; Patel and Tomlinson, 1999; Zotova et al., 2007).
Functional abnormality of neuronal transmembrane ion gradients with altered distribution
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of nodal ion channels (Cherian et al., 1996) has been previously reported. Structural
changes in the form of segmental demyelination in the vicinity of the node of Ranvier
(Jakobsen, 1976; Sima et al., 1988a) along with mild axonal atrophy (Sugimura et al.,
1980) are present in nerves from STZ-induced diabetic rats. In our study, the motor nerve
conduction velocity of the sciatic nerve from sedentary STZ-induced diabetic animals
was decreased by approximately 20-30%. Sensory nerve conduction velocity of the tail
nerve from the same animals, however, remained unaltered. One possible explanation for
this observation could be the difference in the number of myelinated axons present within
these nerves. The sciatic nerve comprises of approximately 30% myelinated axons
(Schmalbruch, 1986), as compared to 11% in the tail nerves (Govindaraju et al., 2007).
Demyelination of sciatic nerve axons results in decreased conduction velocity. However,
since tail nerve has relatively low myelinated axon population, it may only develop slight
decrease in conduction velocity.
Altered distribution of ion channels, including at the node of ranvier in the
myelinated axons is another possibility for the slower conduction velocity in the sciatic
nerve but not in the tail nerve. In this study, forced-exercise protected against diabetes
associated decreases in motor nerve conduction velocity.
Voltage gated Ca2+ currents are enhanced in DRG neurons from chronic diabetic
rats (Hall et al., 1995), raising a possible role for these channels in the development of
painful diabetic neuropathy. Both HVA and LVA T-type Ca2+ channels are expressed in
sensory neurons and appear quite sensitive to acute periods of hyperglycemia. Also, the
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function of these channels are enhanced in parallel with the development of hyperalgesia
(Jagodic et al., 2007). We found a similar enhancement of LVA (T-type) and HVA Ca2+
current densities in small diameter DRG sensory neurons from diabetic hyperalgesic rats.
Moreover, SSI of LVA Ca2+ channels in diabetic DRG neurons was found to be rightward
shifted, indicating enhanced channel availability for activation at physiological resting
membrane potentials. This finding is similar to those previously reported in medium
sized DRG neurons from STZ-treated rats (Jagodic et al., 2007). Forced-exercise not only
diminished diabetes-associated increases in HVA Ca2+ current densities but also
prevented changes in LVA Ca2+ channel SSI. Forced-exercise did not, however appear to
alter the LVA current component in diabetic DRG neurons, suggesting selectivity of
protection.
It is well established that voltage gated Ca2+channels are modulated by ligands,
such as endogenous opioids, that signal through G protein coupled receptors (Catterall,
2000). Decreased levels of endogenous opioids (Williams et al., 2008) and impaired
opioid mediated GPCR signaling (Chen and Pan, 2003) have been reported in neurons
from diabetic animals. In this study, the observed partially normalizing effect of exercise
on HVA current densities of Ca2+ channels could result from minimizing diabetesassociated loss of opioidergic signaling. Modulation of LVA Ca2+ currents by opioids has
not been reported. However, recent studies have implicated G protein signaling in the
inhibition of LVA channels (Wolfe et al., 2003; DePuy et al., 2006).
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Alternatively ligand-mediated enhancement of Ca2+ current density in diabetic
sensory neurons may result from altered phosphorylation of Ca2+ channels (Iftinca and
Zamponi, 2009; Trimarchi et al., 2009) or perhaps increased expression of distinct
channel isoforms (Zhong et al., 2006). We would anticipate, however, that messengermediated changes in channel function would be rapid, giving rise to hyperalgesia within
days, rather than weeks, of hyperglycemic onset. Rapid enhancement of Ca2+ current
density remains a possibility, since DRG neurons from diabetic rats were not evaluated
within this short time frame.
Based on this study, we conclude that forced-exercise delays the development of
painful neuropathy in experimental diabetes, in part, by preventing diabetes-associated
remodeling/modulation of Ca2+ channels in DRG sensory neurons possibly through an
opioid mediated mechanism. However, the basic question of whether glucose directly
plays a role in Ca2+ channel modulation remains to be elucidated.

CHAPTER THREE

D-GLUCOSE DEPENDENT MODULATION OF CaV3.2 α1H CHANNEL FUNCTION

ABSTRACT
The low-voltage activated (LVA) CaV3 (T type) family of calcium channels
modulate neuronal activity, and play a crucial role in the control of cellular excitability.
We and others have previously reported alteration of LVA Ca2+ channel function in an
experimental animal model of diabetic polyneuropathy. In this study, the effects of high
glucose concentration on CaV3.2 α1H, channel subunit properties were investigated. T
type Ca2+ currents from CaV3.2 α1H subunits stably transfected in HEK-293 cells were
recorded using whole-cell voltage clamp electrophysiology. HEK-293 cells cultured for
24h in high-glucose (25 mM) containing media demonstrated a significant increase in
peak CaV3.2 current density (29.7 ± 2.8 pA/pF) , compared to peak current density (21.8
± 1.7 pA/pF) obtained from HEK-293 cells cultured in media containing normal glucose
(5.6 mM).

Kinetics of activation was altered by high glucose, while the channel

inactivation and deactivation time constants, and steady state properties remained
unaffected. Addition of the aldose-reductase inhibitor statil did not attenuate high-glucose
induced enhancement of CaV3.2 currents. These data suggest that high-glucose induced
increase in CaV3.2 channel function involves a mechanism that is independent of D85
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glucose metabolism through the polyol pathway. These preliminary data support a direct
role of D-glucose in altering LVA CaV3.2 channel function.
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INTRODUCTION

CaV3 (T type) family of calcium channels are low-voltage activating channels
present in various tissues such as cardiac muscle, skeletal muscle, and neurons (Catterall,
2000). T type channels play a crucial role in the control of cellular excitability in various
physiological and pathological states (Huguenard, 1996; Llinas and Ribary, 2001). In the
nervous system, these channels modulate neuronal activity, resulting in increased
transmission efficiency and signal amplification (Perez-Reyes, 2003). T channels have
been reported to be involved in the pathophysiology of cardiac arrhythmias (Satoh,
1995), sleep disorders (McCormick and Bal, 1997), epilepsy (Tsakiridou et al., 1995),
fertilization (Talavera and Nilius, 2006), and nociception (Kim et al., 2003). Specifically,
mutations in the gene encoding the CaV3.2 isoform of the T-type Ca2+ channel resulting
in decreased channel activity has been associated with autism spectrum disorders
(Splawski et al., 2006). In comparison, mutations that enhanced T channel activity were
associated with seizure disorders (Heron et al., 2007) and altered nociception (Bourinet et
al., 2005).
In situ hybridization studies have shown a wide distribution of CaV3.2 α1H gene
expression in the central and peripheral nervous system (Talley et al., 1999).
Interestingly, subsets of small and medium sized DRG neurons, as well as sensory
neurons in the superficial lamina of the dorsal horn show expression of CaV3.2 (Talley et
al., 1999), suggesting a possible role in nociception (Shin et al., 2003). In addition,
peripheral pain behavior was attenuated in the CaV3.2 knockout mice (Choi et al., 2007)
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but not in the CaV3.1 knockouts (Kim et al., 2003). In a recent study, silencing of the
CaV3.2 channels in sensory neurons alleviated hyperalgesia associated with STZ-induced
diabetes (Messinger et al., 2009a). As previously reported, STZ-induced diabetes is
associated with significant enhancement of T-type currents (Jagodic et al., 2007; Latham
et al., 2009). The mechanism by which this occurs is unknown. Increased glucose
concentration has been reported to effect the functioning of voltage gated ion channels in
the rat coronary artery (Liu et al., 2001) and mesangial cells (Seal et al., 1995). However,
whether D-glucose has a direct effect on CaV3.2 channels is not clear. In this study, we
investigate the effects of high D-glucose concentration on the biophysical properties of
CaV3.2 α1H, a T type Ca2+ channel subunit stably transfected in HEK-293 cells.
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MATERIALS AND METHODS

Cell culture
HEK-293 cells, stably transfected with CaV3.2α1H, were cultured in minimum
essential medium (Hyclone, MA) containing 5.6 mM (normal) or 25 mM (high) Dglucose (Table 10), supplemented with 10% fetal bovine serum (Cellgro, Herndon , VA),
100 U/ml penicillin, 100 µg/ml streptomycin (Cellgro, Herndon, VA) and 600 mg/ml of
G418 sulfate. Cells were plated onto 12 mm round glass coverslips (Warner instruments,
Hamden, CT) and incubated in a humidified atmosphere of 5% CO2/95% air at 37º C.
Osmolarity of normal and high-glucose containing media was measured using a Vapro
osmometer (Wescor Biomedical Systems, Logan, Utah) (Table 11).
To determine whether elevated levels of D-glucose contribute to the observed
changes in calcium current densities by increased flux through the polyol pathway, HEK293 cells were cultured for 24h in high-glucose containing media in the absence (veh,
0.1% DMSO) or presence (50 or 200 μM) of the aldose reductase inhibitor statil (Tocris,
UK).
Voltage Clamp Electrophysiology
Ca2+ currents elicited from HEK cells were recorded using an Axopatch 200B
amplifier (Axon Instruments, Union City, CA) at 23 ºC. Data was acquired at 1 kHz
using the Digidata 1322A analog-to-digital converter. Ca2+ currents were recorded from
HEK cells bathed in extracellular solution containing (in mM) 5 CaCl2, 140 TEA-Cl, 10
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Hepes and 10 glucose (pH 7.4, 300 mOsm). Borosilicate glass (Warner Instruments,
Hamden, CT) patch pipettes were drawn using a microelectrode puller (Sutter Instrument,
Novato, CA). Resulting patch electrodes had a resistance of 2-4MΩ, when filled with
intracellular solution containing (in mM) 108 CsMeSO3, 4 Mgcl2, 1 Cs-EGTA, 9 HEPES,
5 ATP-Mg, 1 GTP-Li, 15 phosphocreatine-TRIS (pH 7.4, 280 mOsm). Cell capacitance
was measured from a transient current evoked by a 5 mV depolarizing pulse from a
holding potential (Vh) of -90 mV. Only patched HEK cells with capacitance of < 20 pF
and series resistance (Rs) of < 10 MΩ were used. Rs was compensated online (>80%).
Currents were elicited from Vh = -90 mV and depolarized for 250 ms to test
potentials (Vt) = -90 to +50 mV, with 10 mV increments. Activation time constants (τon)
were determined using Vt = -70 mV to + 70 mV from Vh = -90 mV. Rising phase of the
elicited currents were fitted with a single exponential equation. Kinetics of current
inactivation was assessed using Vt = -70 mV to + 70 mV from Vh = -90 mV. Inactivation
time constants (τoff) were determined by fitting the decay phase of the current with a
single exponential equation. Deactivation kinetics were assessed with a 12 ms duration
depolarizing prepulse from Vh= -90 mV to Vt= -30 mV, followed by repolarizing pulses
from -140 mV to -60 mV with 10 mV increments. Resulting tail currents were best fitted
with a single exponential function at all potentials.
Steady state inactivation (SSI) was determined by first stepping the membrane
potential from Vh = -90 mV to pre-pulse voltage levels (V pre : -110 mV to +10 mV, with
10 mV increments) for 1.5 second duration, immediately followed by a depolarizing test
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pulse from -90 mV to -30 mV to evoke T type channel opening. Data were analyzed by
Clampfit (Molecular Devices) and fitted to a single Boltzmann distribution:

where Imax is the maximal current amplitude recorded, V50 is the voltage at which half of
the current is inactivated, k is the voltage dependence (slope) of the function. Steady state
activation curves were obtained using Vt = -90 mV to 0 mV from Vh = -90 mV,
immediately followed by repolarization to -100 mV to evoke inward tail currents that
were then fitted with a single Boltzmann equation.
Statistical Analysis
Data are expressed as the mean ± SEM of N observations unless noted otherwise.
Statistical significance between experimental groups was determined by unpaired
Students t test. p < 0.05 was considered statistically significant.
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RESULTS
D-Glucose induced enhancement of T-type currents in HEK-293 cells
To determine whether D-glucose alters T-type calcium channel function or
properties, HEK-293 cells stably expressing CaV3.2 channels were cultured overnight
(24h) in media containing normal (5.6 mM, NGM) or high (25 mM, HGM)
concentrations of D-glucose. Calcium currents elicited from HEK-293 cells cultured in
NGM exhibited a peak current density of -21 ± 1.9 pA/pF (n=18). By comparison,
calcium currents elicited from HEK-293 cells cultured in HGM exhibited a significantly
(p < 0.05) higher peak current density of -29.6 ± 2.5 pA/pF (n=13) (Figure 12).
Transformed mammalian cells are typically cultured in media containing high glucose
(>25 mM). However, calcium currents elicited from HEK-293 cells cultured chronically
(14 days) in NGM exhibited a peak Ca2+ current density (-17.3 ± 1.4 pA/pF) that was
statistically indistinguishable from acute (24h) exposure conditions (Figure 13). These
data support an acute effect of D-glucose on T-type calcium channel function in these
cells.
D-glucose induced alteration of CaV3.2 channel gating properties
The rate of CaV3.2 channel opening, measured as the activation time constant
(τon), was significantly faster in HEK-293 cells cultured for 24h in HGM, compared to
cells cultured in NGM (Figure 14B). In contrast, the inactivation time constant (τoff), a
measure of channel inactivation, was not significantly altered by elevated D-glucose
concentrations (Figure 15B). Similarly, the deactivation time constant (τdeactivation), a
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measure of channel closing, remained statistically unaltered by elevated concentrations of
D-glucose (Figure 16B).
Effect of D-glucose on CaV3.2 channel steady state properties
The probability of calcium channel opening or the willingness of channels to
open, measured as the steady state activation (SSA), was not significantly altered by
elevated D-glucose concentrations. Specifically, SSA curves obtained from HEK-293
cells cultured for 24h in either NGM (V50 = -31.9 ± 0.6 mV, k = 6.8 ± 0.6) or HGM (V50
= -33.5 ± 0.5 mV, k = 6.5 ± 0.4) were statistically indistinguishable (Figure 18B).
Calcium channel availability, measured as the steady state inactivation (SSI), was also
similarly unaffected by elevated concentrations of D-glucose (NGM, V50 = -59.3 ± 1.1
mV, k = -6.7 ± 0.9; HGM, V50 = -60.2 ± 1.0 mV, k = -7.6 ± 0.9) (Figure 17B).
Aldose reductase inhibition does not alter D-glucose induced enhancement of CaV3.2
currents
To determine whether elevated levels of D-glucose contribute to the observed
changes in calcium current densities by increasing flux through the polyol pathway,
HEK-293 cells were cultured for 24h in high-glucose containing media in the absence
(veh, 0.1% DMSO) or presence (50 or 200 μM) of the aldose reductase inhibitor statil
(Tocris, UK). Vehicle- or statil (50

M)-treated cells exhibited similar peak current

densities of -28.4 ± 4.3 pA/pF or -29.5 ± 2.7 pA/pF, respectively. Increasing statil
concentrations to 200 M did not further alter peak current density (-34.2 ± 2.4 pA/pF).
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These data suggest that D-glucose induced elevation in peak current density occurs by a
mechanism that is independent of the polyol pathway.
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Media

Glucose
concentration*

SD Rats

Blood glucose
levels

Normal
Glucose

5.6 mM

Euglycemic

5.7 ± 0.1 mM

High Glucose

25 mM

Diabetic

27.3 ± 0.2 mM

Table 10. Comparison of in vitro and in vivo glucose concentrations.
(* As reported by the manufacturer)

Media

Osmolarity (mOsm)

Normal Glucose

329 ± 3.7

High Glucose

331.3 ± 0.8

Table 11. Osmolarity measurements of normal and high-glucose containing media.
(Measurements are means of 3 media samples)
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Figure 12. D-glucose enhances CaV3.2 current densities in HEK-293 cells.
(A) Representative Ca2+ current traces evoked by a 250 ms depolarizing pulse from Vh= 90 mV to a Vt= -30 mV from HEK-293 cells cultured 24h in 5.6 mM or 25 mM Dglucose containing media. (B) Current-voltage relationships from HEK-293 cells cultured
in media containing 5.6 mM (open circles, n= 18) and 25 mM D-glucose (closed circles,
n=13). (C) Bar graph comparing peak current densities from B. Data shown in B and C
are the means ± SEM.*, p < 0.05; unpaired Students t test.
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Figure 13. CaV3.2 current densities from HEK-293 cells cultured for 14 days in
normal-glucose containing media.
(A) Current-voltage relationships of CaV3.2 channels from HEK-293 cells incubated
overnight (open circles, n= 13) or 14 days (closed circles, n=5) in media containing 5.6
mM D-glucose. (B) Bar graph showing peak current density. Data shown in A and B are
the means ± SEM. In each case, p > 0.05; unpaired Students t test.
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Figure 14. D-glucose enhances activation kinetics of CaV3.2 channels in HEK-293
cells.
(A) Representative trace showing a calcium current elicited from a Vh = -90 mV to a Vt =
-30 mV. (B) Activation time constants (

on)

from HEK-293 cells cultured in media

containing 5.6 mM (open circles, n=12) or 25 mM (closed circles, n=9) D-glucose. Data
shown are the means ± SEM.*, p < 0.05; unpaired Students t test.

99
A
-30 mV
-90 mV

200 pA
200 ms

60

Tau off (ms)

50
40
30
20
10
0
-50

-30

-10

10

30

50

Voltage (mV)
Figure 15. Effect of D-glucose on inactivation kinetics of CaV3.2 channels in HEK293 cells.
(A) Representative trace showing a calcium current elicited from a Vh = -90 mV to a Vt =
-30 mV. (B) Inactivation time constants (

off)

from HEK-293 cells cultured in media

containing 5.6 mM (open circles, n=10) or 25mM D-glucose (closed circles, n=9). Data
shown are the means ± SEM. In some case, standard errors are less than symbol size.
Observed differences between groups were not statistically significant (unpaired
Student’s t-test).
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Figure 16. Effect of D-glucose on deactivation kinetics of CaV3.2 channels in HEK293 cells.
(A) Representative trace showing a calcium current elicited from a Vh= -90mV to Vt= 30mV, followed by repolarizing pulses (-140 mV to -60 mV, as indicated). (B)
Deactivation time constants (

deactivation)

from HEK-293 cells cultured in media containing

5.6 mM (open circles, n=10) or 25mM D-glucose (closed circles, n=9). Data shown are
the means ± SEM. In some case, standard errors are less than symbol size. Observed
differences between groups were not statistically significant (unpaired Student’s t-test).
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Figure 17. Effect of D-glucose on steady state inactivation of CaV3.2 channels in
HEK-293 cells.
(A) Representative trace showing calcium currents elicited from a Vh = -90 mV to a Vt =
-30 mV. Prior to the test pulse, cells were subjected to a prepulse voltage range from -110
mV to 10 mV, with 10 mV increments. (B) Steady state inactivation (SSI) curves
obtained from HEK-293 cells cultured overnight in media containing 5.6 mM (open
circles, n=12) and 25 mM (closed circles, n=7) D-glucose. Data shown are the means ±
SEM. In some cases, standard errors are less than symbol size. Observed differences
between groups were not statistically significant (unpaired Student’s t-test).
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Figure 18. Effect of D-glucose on steady state activation of CaV3.2 channels in HEK293 cells.
(A) Representative trace showing calcium currents elicited from a Vh = -90 mV to a Vt =
-90 mV to 0 mV and repolarized to -100 mV to evoke inward tail currents. (B) Steady
state activation (SSA) curves obtained from HEK-293 cells cultured in media containing
5.6 mM (open circles, n=11) and 25 mM D-glucose (closed circles, n=5). Data shown are
the means ± SEM. In some cases, standard errors are less than symbol size. Observed
differences between groups were not statistically significant (unpaired Student’s t-test).
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Figure 19. Effect of statil on D-glucose enhanced CaV3.2 current densities in HEK293.
(A) Current-voltage relationship of CaV3.2 channels in HEK-293 cells cultured overnight
in media containing 25 mM D-glucose in the absence (closed circle, n=3) or presence (50
μM, open circle (n=6) or 200 μM, open squares (n=5)) of statil, a potent aldose reductase
inhibitor (ARI). (B) Bar graph comparing peak current densities shown in A. Data shown
are the means ± SEM. Observed differences between groups were not statistically
significant (one-way ANOVA, F(1.02), p>0.05).

104
DISCUSSION
LVA T type calcium currents are enhanced in sensory neurons of diabetic animals
(Hall et al., 1995; Jagodic et al., 2007). However, there are limited studies examining the
mechanism by with D-glucose may affect LVA channels. In this study, we show that
elevated concentrations of D-glucose increase Ca2+ currents elicited from HEK-293 cells
stably transfected with CaV3.2α1H channel subunit. The kinetics of channel opening was
partially altered by elevated concentrations of D-glucose, while channel inactivation,
deactivation, and steady state properties remained unaffected.
Enhanced T-type currents have been previously observed in rat neonatal
cardiomyocytes cultured in high-glucose containing media (Li et al., 2005). Similarly,
neuroblastoma cells cultured in high-glucose media demonstrate increased Na+ currents
with no changes in activation or inactivation kinetics (Wachtel et al., 1995). In this study,
culturing cells overnight in high-glucose (25 mM) containing media enhanced by 30%
peak CaV3.2 Ca2+ current density, compared to cells cultured in normal-glucose media.
The rate of calcium channel activation was also faster in cells cultured for 24h in highglucose media. However, elevated concentrations of D-glucose did not alter the kinetics
of inactivation, deactivation or steady state channel properties, suggesting a
mechanism(s) involving the regulation of channel opening.
Alternatively, D-glucose induced channel activation may not by itself explain the
30% enhancement of peak current density observed. This raises the possibility of
increased channel number. However, HEK-293 cells used here stably express CaV3.2
channel subunits, free of regulatory control.

1H
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Under physiological conditions, extracellular D-glucose enters mammalian
neurons by an insulin-independent facilitative transport mediated by GLUT 1 or GLUT 3
transporters where it is then metabolized by aerobic glycolysis. HEK-293cells used here
similarly express insulin-independent GLUT 1 or GLUT 3 glucose transporters (Castro et
al., 2008). In diabetes, where glucose homeostasis is disrupted, excess intraneuronal Dglucose is atypically shunted to the polyol pathway where it is reduced by aldose
reductase to sorbitol and by sorbitol dehydrogenase to fructose. Glucose-dependent nonenzymatic glycation of intracellular proteins may alter calcium channel function.
However, in this study, inhibition of the polyol pathway with the aldose reductase
inhibitor statil did not prevent D-glucose induced increases in current densities in HEK293 cells, suggesting an alternative mechanism of pathogenicity.
Conversely, enzymatic glycosylation is reported to alter gating properties in
voltage activated sodium channels (Zhang et al., 1999; Stocker and Bennett, 2006). To
address this possibility, studies designed to examine the effect of neuraminidaseassociated deglycosylation of calcium channels in cultured HEK-293 cells are currently
underway. We speculate that neuraminidase will reverse D-glucose induced enhancement
of current density and normalize the rate of channel activation.
In some animal models of diabetes, aberrant elevation of diacylglycerol (DAG)
with concomitant activation of protein kinase C (PKC) have been described (Koya and
King, 1998). PKC activation, by its effects on cellular permeability, contractility, cell
growth, apoptosis, cytokine activation, and cell adhesion is known to mediate various
complications of diabetes (Sheetz and King, 2002). In many cell culture studies,
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increasing the media glucose concentration from 5.6 mM to 22 mM results in elevated
DAG levels and increased PKC activity (Ayo et al., 1991; Shiba et al., 1993). Recent
studies have demonstrated that the CaV3.2α1H channel currents are enhanced by PKC
stimulants (Park et al., 2003) as well as by activation of protein kinase A. However, there
are conflicting reports regarding the ability of PKC isoforms to regulate Ca2+ T-currents
(Perez-Reyes, 2003). In this study, PKC induced enhancement of T-currents remains a
distinct possibility and further studies are needed to address the involvement DAG-PKC
pathways in modulating Ca2+ currents from CaV3.2

1H

channel subunits. Recent reports

also suggest differential CaV3.2 channel behavior depending on the phosphorylation state
of this channel (Hu et al., 2009; Perez-Reyes, 2009). Hyperglycemia-induced alteration
of CaV3.2

1H

subunit phosphorylation state remains another possibility to explain our

observed effects.
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SUMMARY
In this dissertation, we examined the effect of forced-exercise as a behavioral
intervention in modulating the pathogenesis of tactile hyperalgesia in a rat model of type
1 diabetes mellitus. Diabetic rats that were forced to exercise demonstrated a delayed
onset of pain intolerance in the form of tactile sensitivity, compared to non-exercised rats
(Chapter 2). In addition, diabetes failed to induce nerve conduction deficits in rats
subjected to forced exercise. The small diameter DRG neurons, which are generally
associated with pain conduction, demonstrated increased high and low voltage activated
Ca2+ currents in diabetic animals (Chapter 2). Enhanced HVA and LVA Ca2+ currents
promote increased release of nociceptive neurotransmitters and increased cellular
excitability respectively. Exercise partially prevented the diabetes-associated increase in
HVA, but not LVA Ca2+ currents. In addition, diabetes induced depolarizing shift in LVA
steady state inactivation property, indicative of increased cell membrane excitability, was
normalized by forced-exercise (Chapter 2). In-vitro studies confirmed the role of highglucose levels in the enhancement of LVA Ca2+ currents (Chapter 3). However, highglucose did not change the LVA SSI in vitro, suggesting the presence of an additional
factor(s) present in diabetes that are responsible for the observed SSI shift (see Figure
20). Forced-exercise protected against diabetes-induced changes in HVA and LVA
Ca2+channel functions, independent of blood glucose control.
The mechanism by which forced-exercise protects against diabetes associated
neuropathic pain may involve dynamic changes in opiodergic tone. In this study, we
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found that forced-exercise induced protection against diabetes-induced tactile
hyperalgesia was reversed by naloxone, a non-selective opiate receptor antagonist
(Chapter 2).

Forced-exercise

STZ- induced
diabetes

?

DRG Neurons
↑LVA Ca 2+ channel
availability
↑HVA Ca 2+ currents

Hyperglycemia

↑LVA Ca 2+ currents

?

Opioids

Tactile
Hyperalgesia

Nerve conduction
deficits

Figure 20. Working model to explain how forced-exercise may mediate its protection
against diabetes-associated neuropathic pain

Consistent with these findings, previous studies have suggested a role of altered opioidmediated analgesia in diabetes. Reduced potency of morphine and decreased endogenous
opioid levels in diabetic animals are thought to contribute towards a lowered opioidergic
tone, resulting in an enhanced pain state. Opioids inhibit HVA Ca2+ currents through their
respective G protein-coupled receptors (

). Of particular significance, opiate

receptor activation does not affect LVA Ca2+ currents nor alter LVA Ca2+ channel steady
state properties. Hence, in our study, the role of opioids in forced-exercise mediated
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protection against diabetes-associated tactile hyperalgesia is most likely limited to their
effects on HVA calcium channels. This suggests the presence of additional forcedexercise induced factors acting directly or indirectly with the LVA Ca2+ channels to delay
the onset of diabetes associated tactile hyperalgesia.
One possibility may involve heterotrimeric G-protein mediated regulation of LVA
Ca2+ channels. CaV3.2 predominately expressed in DRG nociceptive neurons is inhibited
by the direct binding of Gβ2γ2 to the channel α1 subunit (Wolfe et al., 2003; DePuy et al.,
2006). Alternatively, LVA Ca2+ channels are known to be modulated by nitrous oxide
(Todorovic et al., 2001), phenytoin (Todorovic and Lingle, 1998), certain neuroactive
steroids (Pathirathna et al., 2005), endocannabinoids (Ross et al., 2009) and by the actin
binding protein, Kelch-like 1 (Aromolaran et al., 2010). However, the exact molecular
determinants of LVA Ca2+ channel regulation remains unknown. Exercise-facilitated
neuroplastic changes in pain management remains an exciting direction by which new
neuroprotective therapeutic strategies can be tested.
This dissertative study raises awareness of the importance of exercise in the
management of diabetic neuropathy. Even though our study did not show an effect of
exercise on blood glucose control, exercise had a protective effect on diabetes-induced
pain intolerance and nerve conduction deficits via a non-glucose dependent mechanism.
This finding has several positive clinical implications. Many patients with diabetes suffer
from nerve complications regardless of strict blood glucose control; exercise in these
patients may be beneficial in managing their neurological symptoms. These findings also
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add to the existing clinical literature about the need for supplementing pharmacological
measures with physical exercise in the management of DM.
To the best of our knowledge, this is the first study to demonstrate the effect of
forced-exercise on voltage gated calcium channels. Direct inhibition of VGCC as a
clinical strategy for alleviation of painful symptoms in diabetic neuropathy is limited by
the lack of available N- and T-type selective calcium channel blockers. It would be of
interest to examine clinically the combined effect of exercise and conventional (L-type)
calcium channel blockers on painful diabetic neuropathy. This research study also
underscores the role of exercise in acute pain management. Many patients with painful
conditions arising due to neuralgias, spinal cord trauma, and many forms of neuritis, have
enhanced sensitivity to mildly painful stimuli. Based on this study, it would be worth
exploring the benefits of exercise in these conditions as well.
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